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Abstract 
Acute Lung injury (ALI) and the more severe acute respiratory distress syndrome 
(ARDS) are respiratory maladies that present immense clinical challenges. ALI affects 200,000 
individuals annually and features a 40% mortality rate. ALI can be initiated by both pathogenic 
and sterile insults originating locally in the lungs or systemically. While immense research has 
been poured into this disease in an effort to find a therapeutic strategy, the heterogeneously 
diffuse nature of the disease has not yielded a cure for the disease. Death from this disease is 
strongly attributed to reduced gas exchange from a severely compromised alveolar-capillary 
barrier. The only way currently to manage this disease is through enhanced ventilation and 
hyperoxic therapy.  
 Hyperoxic therapy is a common treatment given to over 800,000 patients each year to 
treat respiratory maladies such as ALI. Prolonged exposure to oxygen at high concentrations 
results in the development of a condition known as hyperoxic acute lung injury (HALI). In this 
disease, the formation of reactive oxygen species damages healthy tissue and impairs gas 
exchange. Hyperoxia is also a well-documented murine sterile lung injury model that replicates 
the symptoms of ALI in lung injury patients. The ability of non-lethal dosages of hyperoxia to 
resolve without lung fibrosis also enables the study of molecules associated with ALI resolution 
and repair, a process not clearly understood 
 Inflammation in ALI is associated with disease progression, however pharmaceutical 
interventions aimed at targeting the inflammatory cascade have failed in clinical trials for ALI. 
x 
Recent reports point to an aberrant injury resolution mechanisms that may be more strongly 
correlated with morbidity and mortality. There seems to be a homeostatic imbalance between 
endogenous inflammation progression and resolution initiation. This is especially the case with 
HALI, as significant ROS generation results in depletion of redox regulating antioxidants. 
Resolution mechanisms associated with ALI in the oxygen toxicity setting is poorly understood. 
 Polyunsaturated fatty acids such eicosapentaenoic acid (EPA) and docosahexaenoic acid 
(DHA) are essential fatty acids that show immense antioxidant and anti-inflammatory action in 
cases of acute injury. The lung mucosa is rich in DHA and following inflammatory insult DHA 
is readily converted to resolution phase interaction products (resolvins), which have shown 
immense proresolutionary potential in recent reports of acute injury. In the presence of aspirin, 
more potent and longer-acting aspirin-triggered resolvins are formed. The effects of resolvins 
and their aspirin triggered epimers have not been studied in an oxygen toxicity setting and are the 
focus of this dissertation. For the first time, we show that one of these resolvin molecules, aspirin 
triggered resolvin d1 (AT-RvD1), can enhance resolution of hyperoxic acute lung injury. In vitro 
results reveals that AT-RvD1 treatment resulted in reduced interaction of two key players in the 
HALI inflammatory cascade, the macrophage and alveolar epithelium. AT-RvD1 was able to 
blunt macrophage cytokine secretion as well as inhibit epithelial cell cytokine secretion and 
adhesion molecule expression. More importantly, AT-RvD1 blunted cytokine mediated 
leukocyte-epithelial cell interaction in vitro. In a sublethal hyperoxic injury model, mice given 
AT-RvD1 following hyperoxia exposure displayed reduced HALI pathological severity. AT-
RvD1 treatment resulted in reduced alveolar-capillary permeability, tissue inflammation, 
proinflammatory mediator secretion, epithelial cell death, and leukocyte influx. Taken together 
these novel results demonstrate the therapeutic potential of resolvins in the oxygen toxicity 
xi 
setting. These results also arouse the idea that resolvins could be used to lessen the comorbidities 
associated with oxygen therapy and improve recovery times of ALI patients.  
1 
 
 
 
 
Chapter 1: Introduction 
Lung Function and Structure 
The lungs and respiratory system are one of the hardest working organ systems in our 
body. While this organ plays an important role in blood vessel mechanics and serve as a shock 
absorber for our heart, the ability of these cone shaped tissue masses to coordinate and promote 
gas exchange for tissues is essential for survival. This is made possible due to the exposure of the 
airway to the atmosphere and the large surface area provided by the lung to facilitate and 
promote gas exchange [1]. Oxygen, inspired nasally or orally, is delivered to the vessels via the 
lungs tree like structure. The trachea receives the oxygenated air and branches into the right and 
left primary bronchi, which further branch off into smaller primary and tertiary bronchi and 
bronchioles[2-4]. At the terminal end of these branches are the alveoli which are the site of 
oxygen-carbon dioxide gas exchange. The lung contain over 700 million alveoli which account 
for a massive surface area which facilitates the gas exchange (shown in Fig 1.1) [5]. Also of 
benefit to this gas exchange is the close proximity of adjacent capillaries which line and wrap 
around the alveoli. The alveolar epithelial cells adjacent to these capillaries provide a very thin 
layer upon which gas can readily diffuse [5]. Resident alveolar macrophages serve as innate 
immune defense to detoxify the lungs of foreign matter and cell debris, as well as initiate the 
inflammatory cascade following lung injury [6].  
  
2 
Alveolar Epithelium 
 The alveolus is the primary site for gas exchange [1,7]. Millions of alveoli contribute to 
702 meters of surface area to facilitate carbon dioxide-oxygen exchange [8]. The alveoli also act 
as a physiological barrier and immunological responder to environmental and pathogenic insults. 
The alveolar epithelium is comprised of two types of pneumocytes, type 1 and type 2 alveolar 
epithelial cells (AECs). Squamous type 1 AECs cover over 80% of alveolar epithelium but only 
represent 20% of alveolar epithelial cells [9]. The cells provide a thin cellular layer enabling gas 
exchange from adjacent capillaries. The squamous morphology of these cells also creates a large 
alveolar surface area which is required due to the relative internal insolubility of oxygen. More 
recently it has been found that these cells aid in fluid transport [10,11]. While these cells play an 
important role in gas exchange, they are very fragile and high amount of cell death from 
pulmonary insults results in a compromised alveolar barrier and pulmonary edema[10]. Type 2 
AECs have a cuboidal morphology and are mainly responsible for the production surface active 
lipoproteins known as surfactants. These surfactants decrease the alveolar surface tension and 
prevent alveolar collapse, a precursor to partial or total lung collapse (atelectasis). Surfactant also 
s helps to facilitate the diffusion of oxygen across the alveolar epithelium [12,13]. Type 2 
pneumocytes are more numerous than 1 AECs, representing approximately 80% of cell 
population but only 20% of the surface area. Type 2 AECs are more resistant to noxious stimuli. 
Following injury, type 2 AECs serve as progenitor cells and terminally differentiate into type 1 
AECs in order to facilitate re-epithelialization of the alveolar barrier [10]. These cells also assist 
in fluid transport to reduce pulmonary edema. These cells are in detail in figure 1.1. 
  
3 
Alveolar Macrophage 
 Representing over 90% of the alveolar resting immune cell population, the macrophages 
are the sentinel cells in healthy alveoli. Alveolar macrophages sense pathogenic stimuli and 
respond by the production of proinflammatory cytokines in order to recruit first responder cells 
such as polymorphonuclear leukocytes (neutrophils) to the site of injury. These cells play a role 
of tissue homeostasis through phagocytosis of apoptotic and necrotic cells [6]. Because of their 
enhanced activity, alveolar macrophages are adaptable and secrete a variety of factors depending 
on the stimulus encountered [14]. In the resolution stage of injury, these macrophages secrete 
pro-resolution factors that stimulate alveolar re-epithelialization and reduced leukocyte 
infiltration[15]. Noxious stimuli caused by trauma, sepsis, aspiration, or oxidative stress can 
result in activation of an immense inflammatory cascade propagated by alveolar macrophages 
that leads to the development of a disease known as acute lung injury [6]. These cells are in 
detail in figure 1.1 
 
Acute Lung Injury Historical Perspective, Epidemiology, and Risk Factors 
ALI is respiratory syndrome that can be characterized by tissue pulmonary edema, altered 
gas exchange, alveolar-capillary membrane dysfunction, and a deregulated and excessive 
inflammatory profile [16-18]. The heterogeneously diffuse nature of this disease makes 
management by Intensive care unit (ICU) physicians a very challenging problem.  This 
progressive respiratory disease represents a progressive spectrum of inflammation and alveolar 
damage, where early onset of the disease is classified as ALI and the more severe form of ALI is 
termed acute respiratory distress syndrome (ARDS)[19]. 
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  Historical Perspective 
Ashbaugh and colleagues described an adult respiratory distress syndrome in 1967 
utilizing a subset of patients under mechanical ventilation as a result of trauma, viral infection, 
and pancreatitis [20,21]. This disease displayed acute onset, with symptoms present within two 
hours of the initial inflammatory stimuli. In this study, 12 patients were found displayed 
symptoms of acute onset tachypnea, systemic hypoxemia, chest x-rays showing panlobular 
infiltration, and atelectasis.  These patients did not respond to conventional respiratory therapies 
and the disease symptoms were very similar to those seen in neonatal respiratory distress 
syndromes. The term adult respiratory distress system was coined as a result of this investigation. 
Over the years adult respiratory distress syndrome has been changed to acute respiratory distress 
syndrome and the clinical criteria for diagnosis of ALI/ARDS has evolved to include early onset 
respiratory distress, diffuse pulmonary infiltrates as measured by chest x-ray, non-cardiogenic 
hypoxemia, and a severity scale of blood oxygenation in order to determine if the patient has 
mild or severe ARDS [22]. 
 Following the initial description of ARDS by Ashbaugh et al., Murray and colleagues 
proposed a lung injury score (LIS) composed of four parameters scored on a scale of 1 to 4 in 
order to decipher ALI/ARDS severity [23].  Once the parameters are scored the LIS is calculated 
by adding the score from each parameter and dividing by the total number of parameters used 
with a score of 0 indicating no injury, 0.1-2.5 indicating ALI, and a score greater than 2.5 giving 
an indication of severe ARDS. The LIS is still a standard that is commonly used today and takes 
into account chest CT or x-ray examination, hypoxemia and oxygen saturation score, lung 
biomechanics, and positive end expiratory pressure (PEEP, ) which is defined as alveolar 
pressure above atmospheric pressure following expiration. This helped to deciphering mild cases 
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of ARDS that are able to be resolved from more severe forms that may lead to more chronic lung 
disease such as pulmonary fibrosis.  
To further develop a uniform definition and to coordinate and properly enroll patients 
into clinical studies to assess therapeutic strategies for ARDS, the North American-European 
Consensus Conference (NAECC) was convened in 1994 [24,25]. At this conference, the term 
acute lung injury as a mild form of ARDS was coined. The recommendation from the panel was 
that a ratio of arterial oxygen partial pressure to fractional inspired oxygen (PaO2/FiO2), a 
hypoxemia indicator, be used to differentiate between ALI and ARDS. A PaO2/FiO2 less than 
300 would suggest ALI and less than 200 would suggest ARDS. The NAECC definition did not 
incorporate PEEP into their proposed definition of ALI or ARDS in order to maintain simplicity 
and uniformity. In order to exclude patients with pulmonary edema as a result of cardiogenic 
disorder, the NAECC definition added the stipulation that the pulmonary artery wedge pressure 
(helps to detect left ventricular failure) had to be less than 18mmHg, with no indication of 
pulmonary hypertension. Diffuse bilateral pulmonary infiltrates, indicative of pulmonary edema, 
was the final criteria used to identify ALI/ARDS in the NAECC definition, however a 
description between ALI and ARDS via chest radiograph was not provided. The major drawback 
to this definition was the failure of an empirical classification of the term acute, which was also a 
drawback of previous ALI/ARDS definitions, however the uniform diagnostic criteria that used 
in NAECC definition has made it easier to classify ALI and ARDS patients for enrollment into 
clinical trials. The more recent Berlin definition (2013) has gone one step further in stratifying 
ARDS into mild moderate and severe via PaO2/FiO2, and has shown better prognostic value in 
helping to determine proper length of ventilation and mortality risk for ALI/ARDS patients [26]. 
  
6 
 Epidemiology and Risk Factors 
ALI, a syndrome of respiratory failure, is a major clinical problem in the United States. 
With a high incidence rate, affecting nearly 200,000 annually and a significant morbidity and 
mortality rate, ALI represents a significant source of health care expenditure with a cost of 3.5–6 
billion dollars annually [27-30]. Annually 75,000 deaths are associated with acute lung injury 
each year, resulting in a 35-40% mortality rate [29]. African Americans demonstrate 
significantly higher ALI mortality rate than Caucasians [31]. The mean age for acute lung injury 
patients is 60 years of age across populations and demographics. Age of patients is a strong 
predictor of disease outcome. Variation among ALI incidence and mortality rate does exist and 
thought to be due to ALI diagnostic reliability and availability of resources in the ICU. The 
annual incidence of 200,000 is dependent on clinical care reporting from the ICU, which would 
suggest that ALI/ARDS occur much more often in the clinical setting than what is traditionally 
reported [32-34].  
As mentioned previously, ALI is a disease of heterogeneous origin and can result from 
sterile or pathogenic injury. While sepsis reports as the most common cause of this syndrome 
with 35-45% of sepsis patients in ICU settings developing ARDS, sterile insults such as severe 
trauma, circulatory shock, pneumonia, and acid aspiration also represent the most common 
clinical insults that lead to acute lung injury development [33,35-38]. ALI can result from 
primary insults local to the lung, or secondary insults that result from systemic injury (Table 1.1) 
Primary insults that lead to acute lung injury include pneumonia, acid aspiration, chest trauma, 
pulmonary thrombus and embolism, reperfusion injury, mechanical stretch related injury and 
near drowning. Second insults that lead to acute lung include but are not limited to sepsis, 
circulatory shock, burns, drug overdose, acute pancreatitis, multi-organ failure and multiple 
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blood transfusion. A history of chronic alcohol abuse, chronic lung disease such as chronic 
obstructive pulmonary disease (COPD) and While it has been difficult to assess the molecular 
determinants of injury, many reports have highlighted an ungoverned inflammatory response as 
key to the progression of ALI and ARDS [32,39].   
 
Acute Lung Injury Pathology 
Irrespective of whether the onset of ALI occurs via primary or secondary insults, ALI 
patients display a similar disease pathology. A critical underlying mechanism associated with 
ALI is the breakdown of the alveolar-capillary membrane [22,23,29,40]. Initial insults such as 
stress and inhalation of noxious chemicals can lead to death of fragile alveolar type 1 and injury 
to alveolar type 2 cells. This leads to a breakdown of the alveolar barrier and allows the alveolar 
space to be flood with edema fluid. Proteins contained in this fluid destabilize the pulmonary and 
increase alveolar surface tension. Because of this process gas exchange is severely compromised 
and hypoxemia develops. Apoptotic epithelium is an early event in ALI that also is a key 
initiator of the acute onset of inflammation that is tied to ALI progression [10,41]. Diseased 
alveoli in ALI is shown in figure 1.1. 
 Activation of normally quiescent alveolar macrophages is a hallmark of alveolar 
inflammation. Alveolar macrophages sense the cell debris from apoptotic and necrotic AECs as 
well as the destabilized pulmonary surfactant and start to polarize to a more proinflammatory 
phenotype. Alveolar macrophages serve as the central effector cells to initiate the early 
inflammatory phase which can occur in as little as 6 hours following injury [5,15,42]. These 
macrophages communicate with adjacent cells through the secretion of proinflammatory 
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cytokines and chemokines such as interleukin-1beta (IL-1β) and tumor necrosis factor-alpha 
(TNF-α). Although TNF-α levels do not predict ALI patient outcome, IL-1β has been shown to 
be the most bioactive cytokine in acute lung injury patients [43,44]. IL-1β concentration 
positively correlates with ALI pathological progression and patient outcomes. The secretion of 
IL-1β in relation to its antagonist IL-1 receptor antagonist (IL-1RA) is 1:1 ratio, however in 
ALI/ARDS patients this ratio can balloon to 10:1 IL-1β. Once secreted, IL-1β can act in an 
autocrine manner to serve as a positive feedback mechanism to enhance cytokine product. 
Paracrine activity on adjacent AECs results in the production of proinflammatory adhesion 
molecules and cytokines such as interleukin-6 and interleukin-8 through a mitogen activated 
protein kinase (MAPK) or nuclear factor kappa-light-chain-enhancer of activated B cells (NF-
κB) dependent mechanism. These cytokines create a cytokine storm or gradient by which attract 
circulating leukocytes such as monocytes and neutrophils to the site of injury [16,45].  This is 
shown in detail in figure 1.2. 
ALI features an immense leukocyte influx into the injured area. Leukocytes such as 
neutrophils migrate into the site of tissue injury utilizing adhesion molecules expressed on the 
alveolar endothelial and epithelial surface. The concentration of neutrophils in the 
bronchoalveolar space positively correlates with severity of ARDS and disease progression 
[9,22]. Neutrophils represent the first responders to the site of injury and release a wide array of 
antimicrobial molecules such as proteinases, cationic peptides, and oxidants. While in pathogenic 
conditions, these antimicrobial molecules are extremely helpful, in cases of sterile injury such as 
oxidant stress related lung injury, the release of these chemicals by neutrophils prove to be 
cytotoxic to healthy alveolar tissue and further activate immune cells [46-51]. Neutrophils that 
have polarized to an inflammatory phenotype and migrate into the tissue area have an average 
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life span of 6 to 8hrs and quickly undergo apoptosis. Neutrophil debris further activates alveolar 
macrophages and enhances the immune response, creating a vicious cycle that does not subside 
in most cases without medical intervention [15]. In patients that recover from acute lung injury, 
curtailing the ungoverned immune response is key to recovery. If left untreated and unattended 
to, loss of surfactant, alveolar flooding, reduced gas exchange, and aberrant repair mechanism 
lead to proliferation of fibroblasts and the development of fibrosing alveolitis which can be 
histologically apparent as soon as five days following the initial injury [52].  
While the pathology of ALI has been well studied, the diffuse nature of insults that lead 
to ALI make it difficult to dissect the molecular mechanisms associated with disease. Further 
complicating the matter is the heterogeneous nature of the injury, as ALI patients do not display 
uniform injury throughout the lung and can demonstrate healthy and diseased tissue in the same 
lobe [53,54]. Cytokines play a major role in propagation of the inflammatory signal that drives 
this disease. Systemic and local cytokine production by epithelial cells and macrophages 
respectively play a key role in leukocyte influx that is also a hallmark of ALI/ARDS. Lung repair 
mechanisms are associated with decrease proinflammatory cytokine production as well as 
increase in proresolutionary mediators. Clearance of these cytokines is associated with injury 
resolution [55,56]. The role of endogenous mediators that contribute to this inflammatory 
regulation is not clearly understood. 
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ALI Treatment Strategies 
Pharmaceutical Treatment Interventions for ALI  
While ALI and ARDS are mediated by inflammation, pharmacological treatments aimed 
at improving respiratory and decreasing inflammation have all failed in clinical trials. Clinical 
trials aimed at delivering glucocorticoids in the late and acute phases, the antioxidant n-
acetylcysteine, and inhaled nitric oxide have all failed to deliver a benefit as reported by the 
National Institute of Health’s ARDS network [57].  
Beta-2 adrenergic agonists (β-2 agonists) have served as a useful therapeutic for 
pulmonary injuries such as asthma and COPD [58,59]. Preclinical data of β-2 agonists for 
treatment of ALI revealed that β-2 agonists reduce pulmonary edema through enhanced fluid 
transport and attenuate inflammation. Although preclinical data was promising, ARDS network 
sponsored clinical trials were stopped due to futility, citing an inability to optimally deliver the 
albuterol to the pulmonary epithelium [57]. COPD and asthma are also diseases of pulmonary 
bronchiolar epithelium which contain significantly more smooth muscle than do alveoli which 
contain only a relatively small amount of smooth muscle. Since β-2 agonists act on smooth 
muscle, this may be a reason why treatment was not effective ALI/ARDS patients. Beneficial 
treatment strategies for ALI mostly result in a form of supportive care, and no effective treatment 
exists for ALI/ARDS patients. Steroids such as glucocorticoids have not only failed to provide a 
benefit to ALI patients, but have also lead to increase complications and increased risk of 
infection.   
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Mechanical Ventilation as Means of Supportive Care 
Mechanical ventilation is a critical clinical intervention used to improve oxygenation and 
reduce hypoxemia in ALI/ARDS patients [10,60]. Mechanical ventilation delivered through the 
tracheal tube combined with PEEP and prone positioning have shown enhanced oxygenation in 
ALI/ARDS patients. Tidal volume accounts for the amount of air that is either inhaled or exhaled 
in a single breath. A large multicenter randomized drug trial sponsored by the ARDS network 
revealed that low tidal volume ventilation conferred significant advantage over patients who 
received high tidal volume ventilation. These patients had reduced ventilator days as well 
displayed decrease organ failure. The inflammatory response associated with ALI and ARDS 
was also decreased, which can be associated with the decrease in barotrauma associated with 
mechanical stretch of the alveolar epithelium [61]. Along with low tidal volume ventilation, 
Fluid management and enteral feeding over parenteral feeding of omega-3 fatty acids has shown 
improvements in patient outcomes. The ARDS networks reports demonstrated that fluid 
management improves oxygenation in ALI/ARDS patients while also decreasing disease 
severity. Patients that receive enteral feeding within 48 hours of mechanical ventilation have 
reduced mortality and morbidity and a lower rate of infection than patients who are fed 
parenterally [62].  
Other forms of supportive care are used to enhance the efficiency of ventilation for 
ALI/ARDS patients. Recent research has found that prone positioning when sleeping can 
enhance oxygen saturation by 50% to 70% during ventilation. Prone positioning can ventilation 
perfusion matching increases lung compliance and decreases fluid buildup in the alveolar space 
[63-66]. Ventilation is also delivered in a tracheal tube with PEEP. Following alveolar injury, an 
intrapulmonary shunt forms which basically when perfused alveoli fail to deliver oxygen to the 
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adjacent blood supply. PEEP reduced intrapulmonary shunt through proper matching of 
ventilation and perfusion. Alveolar congestion and obstruction is also a common hallmark seen 
in injured alveoli, how PEEP enhances alveolar patency and improves alveolar function 
[19,67,68]. Although supportive care such as mechanical ventilation decreases morbidity and 
reduces hypoxemia, outcomes of survival are unaffected. This creates a need for more effective 
treatment strategies aimed at improving ALI/ARDS patient outcome.  
 
Oxygen Therapy and Hyperoxic Acute Lung Injury 
Oxygen Therapy Application 
Oxygen therapy remains the chief form of supportive care for patients who suffer from 
diseases that result in decreased lung function such as ALI. Each year there are over 800,000 
cases that require oxygen therapy, resulting in a healthcare expenditure of 1.8-2 billion dollars 
[69]. The delivery of oxygen to healthy tissues is especially important in chronic lung injury 
cases such as asthma and COPD.  As noted previously, patients who suffer from respiratory 
maladies such as the inhalation of noxious stimuli exhibit poor gas exchange due to lung injury. 
This poor gas exchange leads to arterial hypoxia and subsequent systemic hypoxemia which can 
result in tissue oxygen debt, reduced cell metabolism and physiological functioning which can all 
lead ultimately to organ failure [19,70]. Oxygen supplementation attenuates systemic hypoxemia 
through increased delivery of oxygen from blood to tissue, circumventing the poor gas exchange 
issue faced by lung injury patients. Normally, blood oxygen is attached to hemoglobin, with 
some oxygen being dissolved in blood plasma. When oxygen therapy is administered, the excess 
oxygen saturates the hemoglobin and slightly increases arterial oxygen concentration, the 
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enhanced arterial oxygen results in increased oxygen tension between the capillaries and oxygen 
metabolizing cells [71]. Since the main mechanism of tissue oxygenation relies on diffusion, the 
enhanced oxygen tension results in greater diffusion and transfer of oxygen from capillaries to 
tissue cells. 
 Normal inhalation results in the intake of 21% oxygen from the atmosphere. During times 
of increased oxygen debt, patients can receive oxygen therapy in the form of 24-100% through 
tightly fitting positive pressure flow masks. Patients at the higher end of the spectrum however, 
still face a challenge of decreased oxygen delivery to tissue, even with delivery of higher 
percentage of oxygen (90-100%). This is due to hemoglobin saturation and enhanced dissolved 
oxygen in blood plasma. The loss of oxygen in the blood to plasma dissolution, results in the 
delivery of only 1/3 of required oxygen for resting tissue cells [72]. This can be alleviated 
through hyperbaric oxygen therapy. Hyperbaric oxygen therapy delivers high doses of oxygen at 
a pressure greater than one atmosphere to patients with severe oxygen debt. Exposure to oxygen 
at a pressure three times normal atmospheric pressure results in decreased oxygen dissolution in 
blood plasma and an increase in oxygen delivery to resting cells independent of hemoglobin 
involvement. While oxygen therapy is a necessary form of supportive care that cannot be 
bypassed due to need of oxygen from healthy tissue, there is a narrow margin between effective 
and toxic dosages. A margin that is still clearly not understood [22,73,74]. Furthermore, 
enhanced oxygen delivery can result in excess tissue oxygenation and thus oxygen toxicity. No 
organ is more susceptible to this oxygen toxicity than the lungs, where hyperoxia can cause the 
occurrence of a disease known as hyperoxic acute lung injury [19,75] hyperoxic. 
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 Hyperoxic Acute Lung Injury 
 Oxygen toxicity is a result of excess oxygen exposure to tissues and organs. In the 
alveoli, oxygen toxicity results when the partial pressure of oxygen exceeds that of oxygen in the 
atmosphere. Prolonged breathing of oxygen at a fraction of inspired oxygen greater than .6 can 
lead to serious medical complication and the incidence or exacerbation of an acute lung injury 
termed hyperoxic acute lung injury (HALI) [76]. 
 The first report of HALI in human was from in 1958.  In their report, Prat and colleagues 
discovered increase in alveolar capillary size following hyperoxic overexposure to patients 
suffering from respiratory complications [77]. Various reports would follow to try to further 
classify hallmarks of HALI with such features as a hyaline membrane, but confounding details, 
such as pre-existent acute lung injury and low alveolar fraction of inspired oxygen, would 
decrease the enthusiasm of such claims [78-84]. Two of these cases (Friedmen et al and Nash et 
al) however would like oxygen therapy and ventilation to respiratory complications in neonates 
and death in adults. This caused increase attention to be paid to hyperoxia in the clinical setting. 
Since then case reports investigating HALI have focused on mechanical ventilation utilizing 
PEEP to control the fraction of inspired oxygen administered. However, for patients with severe 
hypoxemia, high dose oxygen and prolonged exposure is unavoidable.  Studies of patients 
exposed to hyperoxic treatment display tracheobronchitis, reduced lung permeability, 
deteriorated lung biomechanics (resistance and compliance), and poor oxygen saturation [85-87]. 
Sustainable measures to improve oxygen therapy efficiency and decrease the harmful effects of 
hyperoxia have not been properly elucidated. 
As with other forms of ALI, HALI is mediated by an acute inflammatory process and if 
left untreated can progress to ARDS. Failure to reduce the increased fraction of inspired oxygen 
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in HALI Is usually fatal. This is due to the uncontrolled production of a significant amount of 
reactive oxygen species (ROS) [19]. ROS are normally produced in cells as a byproduct of 
respiratory burst. Natural antioxidants such as glutathione, reduce ROS and thus limit their 
harmful effects on tissue. In hyperoxic lung injury however the immense amount of reactive 
oxygen species overwhelms and depletes natural antioxidant stores leading to an oxidant-
reduction (Redox) imbalance. This redox imbalance results in the breakdown of the alveolar-
capillary membrane and inability of lung mucosal clearance [88]. Lipid peroxidation results in 
alveolar epithelium as well as DNA oxidation and damage. These signals initiate powerful 
proinflammatory signals and apoptotic cascades in AEC type 2 and type 1 cells respectively 
[75,76,88]. Debris from alveolar epithelial cells and well inactivated pulmonary surfactant 
activate alveolar macrophages who secrete proinflammatory cytokines such IL-1β into the 
alveolar environment [89-92]. Recruitment of neutrophils though cytokine and adhesion 
molecule mediated signaling results in another harmful round of ROS being secreted from 
neutrophil granules. If left untreated or unresolved, there is a fibroproliferative phase that 
develops where enhanced pulmonary interstitial fibroblast activation results in hyaline membrane 
formation and collagen deposition [52,93]. It has been shown previously that this the critical 
point of no return between tissue resolution and chronic injury progression to pulmonary fibrosis 
[55,94-98]. While the molecular determinant involved in the progression of the disease have 
been identified, the molecules involved in HALI resolution have not been thoroughly 
investigated.   
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Hyperoxia in Animal Models of Lung Injury 
Since its discovery in 18th century, oxygen has instantly been thought of as a therapy for 
patients with respiratory complications. In the same breath, research have been skeptical about 
its potentially toxic effects. Shortly after its discovery, Lavoisier found that guinea pigs exposed 
to a high fraction of inspired oxygen died of what he termed “violent inflammation” [99]. 
Postmortem examination of the lungs revealed red discoloration, lung stiffening, and severe 
hemorrhage and clotting. This findings of Lavoisier was confirmed when Watt and colleagues in 
a study of kittens reported extensive inflammation following hyperoxia exposure [100].  In 
another examination of extensive hyperoxia exposure in 1866, Dumas and colleagues discovered 
that post mortem lungs of dogs were considerably stiff, had severe blood clotting and 
coagulation, as well as displayed reduced mucus clearance [100].  Since these initial studies in 
the first 100 years following oxygen discovery, over 50 more studies spanning over 9 species 
have highlighted the debilitating effects of hyperoxia exposure at a fraction of inspired oxygen ≥ 
.8 atmospheres. In general these animals survived lethal oxygen exposure between 3 and 6 days. 
The only animals that have shown particular resistance to oxygen exposure are reptiles and 
amphibians in a normal temperature setting [19]. This suggests that hyperoxia exposure may be a 
reproducible model for ALI. 
Animal models that mimic acute lung injury are essential to demystifying the mechanism 
associated with injury progression and repair. Matute-Bello and collegues describe a good ALI 
model as one that reproduces the classical hallmarks of the disease in both the inflammatory and 
repair phase [101]. Examples of animal models along with their advantages and disadvantages is 
seen in detail in tables 1.2 and 1.3. Ideally, animal models should reproduce the alveolar-
capillary barrier dysfunction, tissue inflammation and leukocyte influx, and enhanced alveolar 
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permeability. Under continuous exposure to disease causing agents, animals should exhibit 
enhanced collagen deposition, decreased lung mechanics and hyaline membrane formation as 
part of the fibroproliferative phase.  However if exposure to disease causing agents such as 
hyperoxia are removed during the initial acute phase (first three days) then the lung injury should 
resolve in most cases [94,102-105]. A look into indexed articles that investigate lung injury 
reveals that 12% utilize the hyperoxia rodent model to study ALI pathology. This model will also 
be used in the in vivo experiments of this dissertation due to its reproducibility and ability to 
mimic clinical ALI hallmarks [19,75,101,106]. Our previous reports, as well those of other 
laboratories, have demonstrated that hyperoxic (95% Oxygen) exposure for 24-72hrs results in 
significant damage to the alveolar epithelium, enhanced proinflammatory transcription factor 
activation, proinflammatory cytokine signaling,  and neutrophil influx [89-92,107-111]. 
Exposure to normal room air (normoxic conditions, 21% oxygen) results in proliferation of type 
2 AECs and healing of the lung tissue with no fibrosis present. Therefore this model is a reliable 
animal model to study lung injury resolution from hyperoxic acute lung injury [101]. Since 
oxygen is a necessary form of supplementary care for ALI patients, the use of the hyperoxia 
model may generate novel therapeutics that can alleviate hyperoxic lung injury and thus increase 
the efficacy of oxygen therapy, and enhance the resolution of ALI/ARDS. 
 
Lung Injury Resolution 
 Acute inflammation is an important response to tissue injury and infection. This well 
regulated process, if left ungoverned can severely compromise lung function and further 
exacerbate the injury. This paradigm of an over active inflammatory process is seen in sterile 
injuries of the lung such as hyperoxic insult, where the innate immune system contributes to the 
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death of healthy tissue through the release of cytotoxic antimicrobial agents [19,106]. If left 
unresolved tissue inflammation can lead to irreparable fibrotic development, where clinical 
interventions are less successful and lung transplant is essential down the line in order to 
decrease morbidity and mortality [52]. In most instances removal the molecular mechanism that 
govern lung injury resolution can finally overpower the inflammatory signals and restore tissue 
homeostasis following clearance of noxious stimuli [94].  
 Although the resolution of injury was known at the tissue level for many years, it was 
thought to occur by means of a passive process where the hallmarks of injury would decrease 
overtime. The flow of chemical mediators such as cytokines and chemokines would decrease 
over their half-life and burn out. Following the clearance of bacteria or removal of noxious 
stimuli, neutrophils would be cleared via phagocytosis or efflux via lymphatic systems to the 
spleen. Enhanced division and subsequent differentiation of AEC type 2 cells into AEC type 1 
cells would repopulate the epithelial barrier and promote edema clearance and boost surfactant 
production (This is shown in detail in fig. 1.3). Recently however the discovery of several 
soluble lipid mediators that seem to play a role in the biochemical process of acute injury 
resolution have caused a paradigm shift in the understanding of injury resolution, providing key 
evidence that hallmarks of resolution such as decreased neutrophil influx are indeed the result of 
an active biochemical process [98,112,113]. These pro-resolution mediators are active in the 
resolving phase of injury which can be defined in terms of maximal inflammatory time point 
(neutrophil influx) to the point where inflammation no longer persists (complete clearance of 
neutrophils) [15,55,96,98,112,114,115]. It is also important to distinguish them as proresolution 
mediators rather than anti-inflammatory mediators.   
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The current depletion therapy paradigm of anti-inflammation results in the attenuation of 
key signals in inflammation. These signals however are also important in the initiation of injury 
resolution patterns. Cyclooxengases and lipoxygenases play important roles in inflammatory 
initiation through the production of prostaglandins and proinflammatory omega fatty acids 
[98,112]. These molecules however also play an important role in the production of key pre-
resolutionary molecules known as resolvins, which will be discussed in detail later in this 
chapter. Cyclooxegase and lipoxygenase inhibitors would partially block the inflammatory 
cascade, but through their inhibition of the molecule would also blunt resolution and contribute 
to persistent inflammation, a well-documented problem in ALI/ARDS. This is also true for 
cytokine therapy of early pro-inflammatory cytokines such as IL-1β and TNF-α, which also play 
a role in injury repair [116]. Thus, endogenous pro-resolution mediators, such as resolvins, that 
decrease the inflammatory response and enhance the active resolution of cellular injury and 
tissue catabasis represent a new and intriguing avenue for therapeutic interventions of a variety 
of maladies associated with unresolved inflammation such as HALI.  
 
Resolution Phase Interaction Productions 
 Experimental models that are self-limiting in nature and resolve on their own have been 
used to discover and characterize molecules that are important aspects of the body’s natural 
proresolution machinery [15,55,94,96,117,118]. Essential polyunsaturated fatty acids (PUFAs) 
such as omega-3s have been noted for their intense anti-inflammatory and antioxidant 
potential[119].  Analysis of essential omega-3 fatty acid eicosapentaenoic acid (EPA, 5Z,8Z,11Z,
14Z,17Z-eicosapentaenoic acid) and docosahexaenoic acid (DHA, 4Z,7Z,10Z,13Z,16Z,19Z-
docosahexaenoic acid) reveals a 0.5%-2.8 and 1.3% percent to 5% composition of total fatty 
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acids respectively. Analysis of cystic fibrosis patients reveals a rich fatty acid content of DHA in 
the lungs of healthy patients. This is an important polyunsaturated fatty acids such as EPA and 
DHA display strong anti-inflammatory properties [98,120]. PUFA’S such as DHA and EPA are 
also readily broken down into pro-resolutionary compounds known as resolution phase 
interaction products (Resolvins). 
 Resolvins are metabolic byproducts of the essential omega-3 fatty acids EPA and DHA. 
Resolvins derived EPA are termed E-series resolvins and resolvins derived from DHA are 
termed D-series resolvins. Resolvins were first identified by LC-MS/MS analysis of murine 
inflammatory exudates in the resolution phase of injury by Serhan and colleagues 
 [112,113]. In this study, it was found cytokine challenge resulted in a rapid generation 
inflammatory leukotriene and prostaglandins in the acute inflammatory phase. Class switching of 
these proinfammatory leukotrienes was associated with decreased neutrophil influx following 
cytokine challenge coupled with aspirin treatment.  These experiments generated new 
compounds that showcased an EPA and DHA backbone and contributed potent pro-resolutionary 
effects at nanomolar and picomolar dosages. Acetylation of the cyclooxygenase enzyme by 
aspirin serves to enhance the effect of both e-series and d-series resolvins [116,120]. This is 
because canonical resolvins that are not aspirin triggered exhibit a very short half-life and are 
quickly enzymatically processed. While these enzymatically altered variants do still possess 
some anti-inflammatory and pro-resolutionary ability, there are far less efficient than 
unprocessed precursors. Aspirin triggered-resolvins of the D series show potent anti-
inflammatory levels in reports of sterile injury, however the effect of aspirin triggered d series 
resolvins have not been investigated in an oxygen toxicity setting. 
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Synthesis of D-Series Resolvins 
D-series resolvins, most notably resolvin D1 (7S,8R,17S-trihydroxy-4Z,9E,11E,13Z,15E,
19Z-docosahexaenoic acid) and resolvin D2 (7S,16R,17S-trihydroxy-4Z,8E,10Z,12E,14E,19Z-
docosahexaenoic acid), are derived from DHA and their synthesis has been previously described 
by Serhan and colleagues [121].  DHA is an essential fatty acid obtained from diet and is present 
in large quantities in the brain, eye, and lung. Following inflammatory injury DHA is converted 
to d-series resolvins in a transcellular pathway involving epithelium or endothelium in the first 
step and leukocytes in the second step. While mechanisms of regulation of resolvin biosynthesis 
are not fully understood, the appearance of these molecules are correlated with the resolutionary 
phase of acute injury [98].  
Canonical d-series resolvins such as resolvin-d1 are converted from DHA in a 
lipoxygenase dependent mechanism (shown in figure 1.4). Following inflammatory injury 
lipoxygenase-15 in the endothelium or epithelium acts on released DHA to form 17S-hydroxy-
DHA (17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid) This 17S-hydroxy-DHA is further 
activated on by neutrophil derived lipoxygenase-5 to produce resolvin-d1. Resolvin D1 has 
shown potent antiinflammtory properties in murine inflammatory acute injury however concerns 
about half-life and rapid inactivation persist [94,98,115,119]. In the presence of aspirin a 
molecule known as aspirin triggered-resolvin d1 is produced and displays significant resistance 
to enzymatic inactivation and is more potent than resolvin d1.  
Aspirin triggered-resolvin d1 is triggered through a similar transcellular pathway this 
time involving the use of cyclooxygenase-2 (COX-2) in the first step of the reaction [112,122]. 
Normally COX-2 is involved in the production of pro-inflammatory omega-6 fatty acids. 
However, in the presence of aspirin, COX-2 is acetylated and there is an alteration in the 
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hydrophobic binding pocket of the molecule that alters substrate preference to the production of 
omega-3 fatty acids. DHA is processed by COX-2 to form 17R-hydroxy-DHA (17R-hydroxy-
4Z,7Z,10Z,13Z,15E,19Z-docosahexaenoic acid) which is then converted to aspirin-triggered 
resolvin d1 (7S,8R,17R-trihydroxy-4Z,9E,11E,13Z,15E19Z-docosahexaenoic acid) [98]. 
Biosynthesis of AT-RvD1 is shown in figure 1.4. The intermediates of both resolvin d1 and 
aspirin triggered-resolvin d1 both have anti-inflammatory biological function. 
 
Summary and Objectives   
 Acute lung injury is a debilitating clinical disease that is hallmarked by overactive 
inflammation and an aggressive inflammatory profile. Noxious stimuli results in the polarization 
of macrophages and the alveolar epithelium to a proinflammtory phenotype characterized by the 
secretion of cytokines such as IL-1β, which has been linked to disease progression and 
pulmonary fibrosis. Investigation into acute lung injury has not resulted in a cure for the disease 
and are maintained via supportive care mechanisms of ventilation and oxygen therapy. While 
oxygen therapy may be a necessary form of supportive care for patients with high oxygen debt, 
the prevalence of oxygen toxicity and reactive oxygen formation can further exacerbate already 
debilitated patients. Hyperoxia in animal models has also proven to be a reliable way to 
investigate lung injury toxicity and resolution, the latter of which is not clearly understood. Since 
pharmacological interventions have not fared clinically with lung injury patients and abberant 
repair mechanism is associated with this disease, investigating endogenous resolution 
mechanisms as an adjuvant to oxygen therapy would be of considerable therapeutic promise. 
Resolvins have displayed considerable therapeutic promise is a wide array of acute injuries. The 
investigation of these molecules in an oxygen toxicity setting is lacking. In  
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this dissertation we plan to investigate the therapeutic promise of D-series resolvins, which are 
reported to have considerable therapeutic benefits at pico- and nanomolar ranges. The resolvins 
will be investigated in vitro for their ability to curb inflammatory functions of macrophages and 
alveolar epithelial cells in vitro. Further, we will examine the therapeutic potential of aspirin-
triggered resolvin d1 in vitro for its ability to decrease HALI severity and enhance lung 
resolution.  
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Tables & Figures 
Figure 1.1: Healthy vs Diseases Alveolus in Acute Lung Injury. The normal alveolar 
epithelium is composed of the alveolar type 1 and type 2 cells. Alveolar type 1 cells provide a 
thin cellular layer with immense surface area in which to facilitate gas exchange between the 
adjacent capillary epithelium. The alveolar type 2 cells maintains alveolar architecture through 
the secretion of tension diminishing pulmonary surfactant. The alveolar macrophage is 
responsible for clearing our alveolar debris as well as sensing of pathogens and noxious stimuli. 
Following inflammatory insult, there is a breakdown in the alveolar capillary barrier due to cell 
death and flooding of the alveolar space. Alveolar edema deactivates pulmonary surfactant and 
activated macrophages secrete proinflammatory cytokines which activate alveolar type 2 cells 
and help to recruit circulating leukocytes.  Cytotoxic molecules secreted by recruited cells such 
as neutrophils contribute to a dangerous inflammatory phase that if left untreated can be fatal. 
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Table 1.1: Causes of Acute Lung Injury. Acute lung injury is a disease of heterogeneously 
diffuse origin and can be caused by primary (local to respiratory system) or secondary (systemic) 
insults. A list of these insults is provided in this table. 
 
 
 
 
 
 
 
 
 
26 
Table 1.2: Examples of Direct Lung Injuries Models. Direct lung injury is one that originates locally in the in the pulmonary space. 
Models that mimic the pathology of local injury are listed in this table 
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Table 1.3: Examples of Indirect Lung Injuries that Lead to ALI: Indirect lung injury is one that originates away from the lung and 
leads to systemic inflammation.. Models that mimic the pathology of systemic lung injury are listed in this table. 
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Figure 1.2: IL-1β mediated activation of the pulmonary epithelial inflammatory response. IL-1β is the most bioactive cytokine in 
lung injury patients. Its secretion in ALI is directly correlated to disease outcome and progression to pulmonary fibrosis. IL-1β 
receptor activation is involved in the activation of proinflammatory epithelial cell functions such as cytokine secretion, adhesion 
molecule expression, and leukocyte trafficking. This thought to work through a MAP kinase and NF-κB mediated pathway.  
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Figure 1.3: Inflammation vs Resolution Time points. A. Insults in acute injury lead to the activation of resident immune cells and 
the secretion of cytokines and chemokines.  Once this inflammatory process is initiated it proceeds with the recruitment of leukocytes, 
which can further deteriorate the alveoli with the release of toxic molecules such as ROS. Failure to fix this will result in chronic 
injury. Resolution however involves the use of specialized lipid mediators known as resolvins to decrease leukocyte influx, enhance 
clearance of dead cells and reestablishment of the fragmented alveolar-capillary barrier. B. A temporal representation of inflammation 
vs resolution is depicted above. 
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Figure 1.4: Biosynthesis of D-series Resolvins. Docasahexaenoic acid (DHA) is an essential part of our diet. DHA also serves as 
an endogenous anti-inflammatory molecule. Following injury, DHA is cleaved in a transcellular pathway as shown above to produce 
pro-resolution molecule resolvin-d1. In the presence of aspirin, cyclooxygenase is acetylates yielding more omega-3 products. Aspirin 
acetylation leads to the production of the more stable aspirin triggered epimer of resolvin d1 as shown. 
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Chapter 2: Resolvins Decrease Hyperoxia Mediated Macrophage and Epithelial Cell 
Interaction through Decreased Cytokine Secretion. 
 
Abstract 
Inflammation is a key hallmark of ALI and is mediated through ungoverned cytokine 
signaling. One such cytokine, interleukin-1beta (IL-1β) has been demonstrated to be the most 
bioactive cytokine in ALI patients. Macrophages are the key players responsible for IL-1β 
secretion into the alveolar space. Following the binding of IL-1β to its receptor, “activated” 
alveolar epithelial cells show enhanced barrier dysfunction, adhesion molecule expression, 
cytokine secretion, and leukocyte attachment. More importantly, it is an important communication 
molecule between the macrophage and alveolar epithelium. While the molecular determinants of 
this inflammatory event have been well documented, endogenous resolution processes that 
decrease IL-1β secretion and resolve alveolar epithelial cell activation and tissue inflammation 
have not been well characterized. Lipid mediator Aspirin-Triggered Resolvin D1 (AT-RvD1) has 
demonstrated potent pro-resolutionary effects in vivo models of lung injury; however, the 
contribution of the alveoli to the protective benefits of this molecule has not been well documented. 
In this study, we demonstrate that AT-RvD1 treatment lead to a significant decrease in oxidant 
induced macrophage IL-1β secretion and production, IL-1β-mediated cytokine secretion, adhesion 
molecule expression, leukocyte adhesion and inflammatory signaling.  
THP-1 macrophages were treated with hydrogen peroxide and extracellular ATP in in the 
presence or absence of AT-RvD1 (1000-.1nM). A549 alveolar-like epithelial cells were treated 
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with IL-1β (10 ng/mL) in the presence or absence of AT-RvD1 (0.1 uM). Following treatment, 
cell lysate and cell culture supernatants were collected for Western blot, qPCR and ELISA analysis 
of pro-inflammatory molecules. Functional consequences of IL-1β induced alveolar epithelial cell 
and macrophage activation were also measured following treatment with IL-1β ± AT-RvD1.  
Results demonstrate that macrophages exposed to H2O2 and ATP in the presence of 
resolvins show decreased IL-1β production and activity. A549 cells treated with IL-1β in the 
presence of AT-RvD1 show a reduced level of proinflammatory cytokines IL-6 and IL-8. Further, 
IL-1β-mediated adhesion molecule expression was also reduced with AT-RvD1 treatment, which 
was correlated with decreased leukocyte adhesion. AT-RvD1 treatment demonstrated reduced 
MAP-Kinase signaling. Taken together, our results demonstrate AT-RvD1 treatment reduced IL-
1β-mediated alveolar epithelial cell activation. This is a key step in unraveling the protective 
effects of resolvins, especially AT-RvD1, during injury.  
  
Introduction 
Airway inflammation is a key hallmark in inflammatory lung disease such as acute lung 
injury (ALI) and acute respiratory distress syndrome (ARDS) [1,2]. Following injury there is an 
immediate release of proinflammatory mediators that serve to enhance the inflammatory response. 
One of these inflammatory mediators, IL-1β is the most bioactive cytokine in the lungs of acute 
lung injury patients [3]. IL-1β when secreted into the alveolar space (mainly by alveolar 
macrophages), can act through its receptor IL-1R to upregulate mechanisms associated with 
vascular and tissue remodeling, cytokine and chemokine expression, cellular attachment, as well 
would repair [4-6]. In vitro murine models have shown that proinflammatory mediators play a key 
role in the pathology of ALI [7-16]. IL-1β’s cellular binding partners include macrophages, 
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endothelial cells, and the alveolar epithelium. The alveolar epithelium is a key regulator of the 
proinflammatory and anti-inflammatory immune response. 
 The role of alveolar epithelium in inflammation is still not yet clear. Previously thought to 
participate in surfactant production and barrier function, more studies are elucidating the role of 
the alveolar epithelium in the inflammatory stage in response to proinflammatory mediators such 
as IL-1β [17]. IL-1β serves to activate the alveolar epithelium and enhances the expression of 
proinflammatory products such as cytokines, chemokines, adhesion molecules, and pro- 
inflammatory lipid mediators [3]. IL-1β binding has also been demonstrated to greatly diminish 
the physical barrier properties and permeability of the alveolar epithelium through decreased tight 
junction formation. More important to the persistent inflammation seen in ALI, the alveolar 
epithelium plays an integral part in the recruitment of circulating leukocytes to the area of injury 
[18,19]. The release of cytokines and expression of adhesion molecules by the activated alveolar 
epithelium aids in the cytokine gradient and attachment points used by leukocytes to migrate into 
the alveolar space. The consistent uncontrolled extravasation of these leukocytes, such as 
neutrophils and monocytes, into injurious tissue is well documented to be a key event in the 
development and progression of inflammatory lung disease [20-23]; however, the endogenous 
resolution mechanisms and catabasic processes used by our body to resolve this imbalance has yet 
to be clarified.  
 Resolution phase interaction products (resolvins) are lipid mediators derived from omega-
3 free fatty acids eicosapentanoic acid (EPA) and dicosahexanoic acid (DHA) [24-27]. In the 
presence of aspirin, the aspirin-triggered forms of these lipid mediators are produced. Aspirin-
triggered resolvins, unlike the traditional resolvins, are resistant to oxidation and therefore are able 
to show prolonged effect in comparison with traditional resolvins [25]. We have recently 
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demonstrated the ability of aspirin triggered-resolvin D1 to enhance resolution of hyperoxic acute 
lung injury (HALI) [28]. Resolvins show therapeutic promise in many different disease models 
[24,25,29]; however, their role on the activation of the alveolar epithelium has not been elucidated. 
In this study, we investigated the effects of aspirin-triggered resolvin D1 (AT-RvD1) on IL-1β-
induced alveolar epithelial cell activation. The results indicate that AT-RvD1 modulates IL-1β-
mediated epithelial cell cytokine secretion and adhesion molecule expression. Further, our results 
also demonstrated that AT-RvD1 also inhibit IL-1β-stimulated leukocyte adhesion. In addition, 
AT-RvD1 decreased the activation of the p38 and ERK map kinase pathways, which are known 
to be involved in the propagation of the inflammatory cascade in the alveolar epithelium. Our 
results suggest that targeting the alveolar epithelium with resolvins, is a novel way to reduce 
inflammation in the alveolar space. 
 
Materials and Methods 
 
Cell Culture 
A549 cells are a human alveolar epithelial cell line derived from a human lung 
adenocarcinoma patient. THP1 cells are a human monocytic cell line obtained from an acute 
myeloid leukemia patient. Both cell lines were purchased from American Type Culture Collection 
(ATCC, Manassas, VA). A549 cells and THP1 express all the components necessary to serve as 
an effective cell line to model epithelial cell activation and monocyte adhesion, respectively. A549 
cells were cultured in Dulbecco’s Modified Eagle Medium/F12 Nutrient mix (1:1 ratio, Gibco, 
Grand Island, NY) complete with 10% fetal bovine serum (FBS, Gemini Biologicals, Sacramento, 
CA) and 1% penicillin/streptomycin mixture (P/S, Gibco, Grand Island, NY). THP1 cells were 
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used for cytokine, caspase and adhesion assays and were cultured in RPMI 1640 medium (Gibco, 
Grand Island, NY) complete with 10% FBS (Gemini Biologicals, Sacramento, CA), 1% P/S and 
1% sodium pyruvate (Gibco, Grand Island, NY). Both cell lines were maintained in a humidified 
atmosphere at 37°C and 5% concentration. Cells were treated as mentioned in each section. 
 
Cytokine Analysis 
A549 cells were seeded in 12 well plates at a density of 0.5 x 106 cells/mL. Following 24 
hr incubation to reach confluence, cells were serum starved for 6 hrs. After serum starvation A549 
cells were treated with IL-1β (10 ng/mL, R&D Systems, Minneapolis, MN) in the presence or 
absence of aspirin-triggered resolvin D1 (100 nM, AT-RvD1, Caymen Chemicals, Ann Arbor, MI) 
for 6 hrs. Optimization of AT-RvD1 treatment was done using varying AT-RvD1 concentrations 
in THP1 experiments (0.1-1000nM). Cells receiving AT-RvD1 were pretreated with AT-RvD1 for 
30 minutes prior to addition of IL-1β or vehicle. THP-1 cells were seeded in 12 well plates at a 
density of .5x106 cells per well. They were allowed to reach 85/%-90% confluence and then were 
serum starved in the presence of priming agent phorbol-12-myristate-13-acetate (PMA, 10ng/mL). 
Following treatment with PMA cells were primed with LPS to generate pro-IL-1β and then treat 
with inflammasome activators ATP and  hydrogen peroxide in the presence or absence of 
docosahexaenoic acid, EPA, Resolvin D1 (RvD1), Resolvin D2 (RvD2) or AT-RvD1, all at 
indicated dosages. All resolvins as well as DHA and EPA were obtained from Caymen Chemicals 
(Ann Arbor, MI). Following the treatment of A549 and THP1 cells, supernatants were collected 
and used for cytokine analysis via ELISA. ELISA for IL-1β (E-bioscience, San Diego, CA), IL-6 
(E-bioscience, San Diego, CA) and IL-8 (R&D Systems, Minneapolis, MN) was performed 
following the manufacturer’s instructions. Absorbance measurements were made using an 
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absorbance plate reader (Biotek, Winooski, VT) and concentrations were obtained using 
manufacturer provided standards. ELISA for active caspase-1 (R&D Systems, Minneapolis, MN) 
in THP1 cells was performed using cell lysates and measured using absorbance readings. 
 
Quantitative Real Time-PCR (qPCR) 
A549 cells were seeded in 12 well plates at a density of 0.5 x 106 cells/mL. Following 24 
hr incubation to reach confluence, cells were serum starved for 6 hrs. After serum starvation A549 
cells were treated with IL-1β (10 ng/mL) in the presence or absence of AT-RvD1 (100 nM) for 6 
hrs. Following treatment, cells were resuspended in Trizol (Invitrogen, Grand Island, NY) and 
mRNA was harvested following the manufacturer’s instructions. 1 ug of RNA for each sample 
was reverse transcribed into cDNA using the iSCRIPT cDNA synthesis kit (Bio-Rad, Hercules, 
CA) according to the manufacturer’s instructions. Forward and reverse primers for 18S ribosomal 
RNA as well as ICAM-1 were purchased from Integrated DNA Technologies (Coralville, IA). 
Primers were used in a final concentration of 100 nM and assays were done in triplicate. Human 
ICAM-1 and 18S ribosomal DNA were amplified using the following primers: ICAM-1F:5’-AGC 
AAT GTG CAA GAA GAT AGC CAA-3’, ICAM-1R: 5’-GGT CCC CTG CGT GTT CCA CC-
3’, 18sF: 5′-TAA CGA ACG AGA CTC TGG CAT-3′ and 18sR: 5′-CGG ACA TCT AAG GGC 
ATC ACA G-3′. qPCR was performed using the SYBR green master mix and CFX96 system (Bio-
Rad, Hercules, CA). Normalization of ICAM-1 expression was achieved by comparing the 
expression of 18S ribosomal RNA for the corresponding sample. 
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Epithelial Cell-Monocyte Adhesion Assay 
The epithelial monocyte assay was performed as previously described with minor 
modification [30]. Briefly, A549 cells were activated for 6 hrs with IL-1β in the presence or 
absence of AT-RvD1. After treatment, the cells were washed with PBS and new media was added 
to each well. 30 minutes prior to end of the 6 hr incubation, monocytes were loaded with calcein 
AM dye (Life Technologies, Carlsbad, CA) and immediately added in the activated A549 cells. 
After a 30 minute incubation period, unbound monocytes were washed away with PBS twice and 
fluorescent images were taken.  
 
Calcein AM Loading of Monocytes 
Calcein AM was purchased from Invitrogen (Grand Island, NY) and diluted to a working 
stock of 1 mM and stored in -20°C in light sensitive microcentrifuge tubes. Prior to the experiment, 
THP1 cells were loaded with calcein AM at a final concentration of 10 uM for 30 minutes at 
normal cell culture conditions in a humidified incubator. Following incubation, cells were washed 
twice with PBS (without Ca2+ and Mg2+) and diluted at a final concentration of 0.5 x 106 cells/mL 
prior to the addition of cells to the plates containing IL-1β activated A549 cells. 0.5 x 106 cells/mL 
was added to each treatment for microscopy analysis. For plate reader analysis, 5 x 104 THP1 cells 
were used. 
 
Adhesion Assay for Alveolar Epithelial Cell-Monocyte Interaction 
1 x 106 and 1 x 105 A549 cells were seeded in 12 well and 96 well plates, respectively. 
After overnight incubation in complete medium, cells were serum starved for 6 hrs. After serum 
starvation A549 cells were treated with IL-1β (10 ng/mL) in the presence or absence of AT-RvD1 
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(100 nM) for 6 hrs. Cells receiving resolvins were pretreated with AT-RvD1 for 30 minutes prior 
to addition of IL-1β or vehicle. Following treatment, the aforementioned amount of THP1 cells 
were added to each plate and co-incubated with A549 cells for 30 minutes. After incubation of 
A549 cells with THP1 cells, the plate washed with PBS four times to ensure only bound THP1 
cells were left in the plate. Microscopy (12 well plates) as well as relative fluorescence intensity 
measurements (96 well plates) were used to analyze monocyte adhesion to treated A549 cells. 
Images were taken and plates were read using excitation-emission spectra of Ex: 495nm/Em: 
515nm.  
 
Electric Cell-Substrate Impedance Sensing (ECIS) 
A549 cells were seeded on 8W10E+ ECIS arrays (Applied Biophysics, Troy, NY) at a 
density of 0.5 x 106 cells/mL.  Cells were grown to a confluence as measured by a reading of 10 
uF on the ECIS System (Applied Biophysics, Troy, NY). After achieving confluence, A549 cells 
were subjected to serum starvation and were treated with IL-1β (10 ng/mL) in the presence or 
absence of AT-RvD1 (100 nM) for 6 hrs. Cells receiving resolvins were pretreated with AT-RvD1 
for 30 minutes prior to addition of IL-1β or vehicle. Resistance measurements were taken for a 
period of 48 hrs. Three samples were used and 4 measurements were taken at each time point to 
mitigate inter- and intra- sample variability. Culture medium served as the electrode and barrier 
function was analyzed as a function of impedance of a cell-covered electrode. A 1-V, 4,000-Hz 
alternating current signal was supplied through a 1-MΩ resistor to approximate a constant-current 
source. ECMS 1.0 software (CET, Coralville, IA) was used to measure the in-phase voltage 
resistance and capacitance. Epithelial barrier function of A549 cells was expressed as TER, which 
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was normalized to a time-zero baseline. Epithelial monolayers that did not achieve a baseline TER 
of 5,000 Ω or higher were excluded from this study. 
 
Western Blot Analysis 
As with ELISA, A549 cells were seeded in 12 well plates at a density of 0.5 x 106 cells/mL. 
Following 24 hr incubation to reach confluence, cells were serum starved for 6 hrs. After serum 
starvation A549 cells were treated with IL-1β (10 ng/mL) in the presence or absence of AT-RvD1 
(100 nM) for 6 hrs. Cells receiving resolvins were pretreated with AT-RvD1 for 30 minutes prior 
to addition of IL-1β or vehicle. Following A549 cell treatment, cell lysates were collected using 
RIPA Buffer (25 mM Tris-HCl (pH 7.6), 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 
0.1% SDS, Thermo Scientific Pierce, Rockford, IL). After lysate extraction, protein concentration 
was determined with a BCA assay (Thermo Scientific Pierce, Rockford, IL) following the 
manufacturer’s specific instructions. 40 ug of protein was prepared, loaded, and separated on 8, 
10, 12 or 15% SDS-PAGE gels (depending on the molecular weight of the protein of interest) and 
then transferred onto a PVDF membrane (Thermo Scientific Pierce, Rockford, IL) using 
electrophoresis. Membranes were blocked for 1 hr in 5% non-fat dry milk and then incubated with 
total and phosphorylated p38, ERK 1/2, and SAPK/JNK antibodies (Cell Signaling, Boston, MA). 
Membranes were then washed and probed with HRP-Conjugated secondary antibodies (Jackson 
ImmunoResearch Laboratories, West Grove, PA). HRP activity was detected using an enhanced 
chemiluminescence (ECL) kit according to the manufacturer’s instructions (Thermo Scientific 
Pierce, Rockford, IL).  
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Statistical Analysis 
All experiments were performed at least in three different experiments. Statistical 
significance was analyzed using a paired student t-test and a 1-way analysis of variance where 
applicable. A p- value less than 0.05 was considered to be statistically significant. 
 
Results 
 
 Resolvins Inhibit IL-1β Secretion in THP1 Cells in a Dose Dependent manner 
Macrophages are the major players involved in the initiation of the proinflammatory 
cytokine cascade.  Macrophage mediated secretion of IL-1β, serves as an initiator of the 
proinflammatory response and results in upregulation of proinflammatory genes on IL-1β target 
cells [3]. Previously we have demonstrated that oxidant exposure leads to macrophage IL-1β 
secretion, ultimately resulting in enhanced alveolar epithelial cell permeability [6]. 
 In order to see whether resolvins can attenuate oxidant mediated IL-1β secretion in 
macrophages, THP-1 monocytes were differentiated into macrophages and treated with hydrogen 
peroxide and ATP, both well-known inducers of IL-1β secretion in macrophages (Fig 2.1). We felt 
that this model of oxidant stress was physiologically relevant because our previous reports have 
shown that hyperoxia signaling leads to enhanced extracellular ATP release which serves as an 
adjuvant to oxidative stress to further enhance cytokine secretion [6]. Treatment with resolvin 
precursors DHA and EPA resulted in a significant reduction of resolvin in IL-1β secretion 
following oxidant-ATP treatment. Resolvins also leads to a significant decrease in IL-1β secretion 
with AT-RvD1 having the most significant decrease. More importantly these resolvins were able 
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to accomplish significant attenuation of IL-1β secretion at the low nanomolar ranges in comparison 
to their parent fatty acids which achieved significane at the micromolar dosage (Fig 2.2).  
To further confirm this we looked at resolvins ability to inhibit the activity of caspase-1, 
the primary processing enzyme. Results showed that resolvins RvD1 and AT-RvD1 show 
significant inhibition of caspase-1 activity following oxidant-ATP mediated activation. Taken 
together these results highlight an important role for resolvins in decreasing the release of early 
macrophage mediated cytokine IL-1β in oxidant related injury.  
 
Resolvin Treatment Results in Decreased Macrophage Induced Alveolar Epithelial 
Cytokine Secretion. 
Our previous reports have demonstrated that oxidant mediated macrophage cytokine 
secretion results in increased permeability of alveolar epithelial cells. Previous reports have also 
highlighted that this interaction between the macrophages and epithelial cells are cytokine 
dependent. Since polarization of epithelial cells leads to an enhanced inflammatory state and is an 
important part of the inflammatory cascade, we wanted to assess resolvins’ ability to blunt the 
macrophage to epithelial cell interaction. We also wanted to assess whether the protective role was 
mediated through reduced IL-1β. To test this THP-1 monocytes were differentiated and treated 
with ATP and hydrogen peroxide in the presence or absence of resolvins RvD1 and AT-RvD1. 
Supernatants were collected and used to treat A549 cells for 1 hour. Following treatment 
supernatant was collected and analyzed for proinflammatory mediator and neutrophil 
chemoattractant IL-8. Results reveal that both RvD1 and AT-RvD1 blunted the ability of 
supernatant from oxidant-ATP treated cells to induce A549 cells to secrete IL-8. Since AT-RvD1 
showed a more significant increase in macrophage studies and is more resistant to enzymatic 
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cleavage, we chose to use it as our primary molecule for resolvin investigation going forward in 
this dissertation.  
 
AT-RvD1 Decreases IL-1β-mediated Proinflammatory Cytokine Release in Alveolar 
Epithelial Cells 
Alveolar epithelial cells are activated when in the presence of proinflammatory molecules 
such as IL-1β [3].   Following activation, secretion of proinflammatory mediators such as IL-8 and 
IL-6 serves to propagate the inflammatory signal to the lung interstitium and vasculature [6,31].   
To determine whether AT-RvD1 inhibited the rate of proinflammatory cytokine secretion by 
alveolar epithelial cells, A549 cells were grown and the secretion of IL-6 and IL-8 were 
investigated. As shown in Fig. 2.5A and 1B, A549 cells treated with IL-1β (10 ng/mL) display an 
increase in IL-6 and IL-8 secretion. However, this increase is attenuated for both cytokines in the 
presence of AT-RvD1 (100 nM). No significant difference was observed between the resolvin and 
control groups. While the release of both cytokines were significantly dampened with resolvin 
treatment, resolvins were able to reduce the IL-1β-mediated IL-6 (Fig. 2.5B) by greater than 60% 
(p < 0.001) in comparison to IL-1β treatment alone. 
 
AT-RvD1 Attenuates IL-1β-induced Adhesion Molecule Expression in Alveolar 
Epithelial Cells 
Proinflammatory cytokines such as IL-1β and IL-6 have been demonstrated to induce the 
expression of adhesion molecules such as intercellular adhesion molecule-1 (ICAM-1, CD54) 
[32,33]. ICAM-1 is a transmembrane protein that plays an important role in the transepithelial 
migration of leukocytes into the epithelium. We hypothesized that the reduced cytokine secretion 
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would result in decreased ICAM-1 expression. To investigate the effect of resolvins on IL-1β-
induced A549 ICAM-1 expression, A549 cells were treated with IL-1β (10 ng) in the presence or 
absence of aspirin-treated resolvin D1 (100 nM). Following IL-1β Treatment, ICAM-1 expression 
increased to its maximal value. 10 minute pretreatment of A549 cells with AT-RvD1 prior to IL-
1β led to a 35% decrease (p < 0.05) in ICAM-1 expression (Fig. 2.6).   
 
AT-RvD1 Inhibits IL-1β-mediated Monocyte and Alveolar Epithelial Cell Adhesion  
Circulating leukocytes extravasate out of vasculature and migrate into damaged tissue 
following acute injury. This is aided by the secretion of proinflammatory molecules such as IL-
1β, IL-8, and IL-6 [34]. Once out of the vasculature, adhesions molecules such as ICAM-1 play a 
key role in the extravasation into the injured lung tissue [35]. Since resolvins decreased cytokine 
and ICAM-1 secretion and expression, respectively; we hypothesized that resolvins would 
decrease leukocyte adhesion to alveolar epithelial cells.  To investigate this, A549 cells were 
treated with IL-1β (10 ng/mL) in the presence or absence of AT-RvD1 (100 nM). Following IL-
1β treatment, calcein AM loaded THP1 monocytes were loaded into the wells containing A549 
cells and co-cultured for 30 minutes. Image analysis shows that monocyte adhesion (as seen with 
green fluorescent dots) was significantly enhanced with IL-1β treatment alone in comparison to 
control. Monocyte adhesion was significantly diminished when A549 cells was pretreated with 
AT-RvD1 (Fig 2.7A).  Treatment with AT-RvD1 alone did not significantly enhance monocyte 
adhesion. In a separate experiment, the adhesion assay was reproduced in 96 well plates and 
relative fluorescent intensity was measured to further quantify our results. Resolvin treatment 
resulted in greater than 50% reduction in IL-1β-mediated THP1-A549 cell adhesion in comparison 
to cells that were treated with IL-1β alone (Fig. 2.7B). This further confirmed the difference seen 
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in the fluorescence microscopy analysis.  In an attempt to mitigate the effect of cellular variability, 
only confluent monolayer following IL-1β treatment was used for the adhesion assay. These 
monolayers are shown in the bright field images (Fig. 2.7A). We did not detect a difference in 
monolayer consistency among the groups following IL-1β treatment. 
 
AT-RvD1 Fails to Rescue Barrier Dysfunction In Alveolar Epithelial Cells 
Alveolar epithelial cells form alveolar capillary barrier between the alveolar epithelium 
and the lung microvasculature. This barrier function of the alveolar epithelium also preserves the 
microenvironment of the alveoli and alveolar capillaries. Disruption of this barrier in the presence 
of proinflammatory mediators such as IL-1β leads to alveolar thickening, pulmonary edema, and 
diminished gas exchange [3,7,15,36-38].  To assess the effect of resolvins on IL-1β-induced barrier 
dysfunction, transepithelial permeability (TER) was analyzed using electric cell-substrate 
impedance sensing (ECIS). A549, seeded in ECIS electrode arrays, were treated with IL-1β (10 
ng/mL) in the presence or absence of aspirin-triggered resolvin D1 (100 nM) (Fig. 2.8). TER was 
recorded by the ECIS system for 48 hrs. Both resolvin alone and control treatment showed a small 
decrease in TER after 48 hrs. There was no significant difference in TER between the groups 
treated with IL-1β and resolvins in comparison to those treated with IL-1β alone. Resolvin 
pretreatment did slightly improve the decrease in barrier resistance caused by IL-1β in comparison 
with IL-1β treatment alone. Resolvins RvD1 and AT-RvD1  
 
AT-RvD1 Attenuates IL-1β-induced MAP Kinase Phosphorylation 
Mitogen activated protein kinases (MAPKs) are important regulators of the immune 
response in many myeloid and non-myeloid lineages such as alveolar epithelial cells. When 
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activated these proteins play an important role in activating transcription factors that are necessary 
for transcription of proinflammatory events following injury such as cytokine production, barrier 
dysfunction, and adhesion molecule expression. The binding of IL-1β to its receptor, (IL-1R), leads 
to the activation of various pathways including those of MAPKs. Since we observed a change in 
IL-6 and IL-8 secretion as well as a decrease in ICAM-1 expression, we hypothesized that resolvins 
decrease the inflammatory effects of alveolar epithelial cells through decreased MAPK activation. 
To test this, A549 cells were treated with IL-1β (10 ng/mL) in the presence or absence of aspirin-
triggered resolvin D1 (100 nM). Following treatments, cell lysates were collected for Western blot 
analysis of p38, ERK 1/2, and SAPK/JNK MAPK. These three MAPKs play a key role in 
propagating the inflammatory signal following IL-1β stimulation. AT-RvD1 pretreatment 
decreased p38 and to a lesser extent ERK phosphorylation at 5 and 10 minutes (Fig 2.9 A-B). No 
change was observed between the control and AT-RvD1 alone samples. AT-RvD1 pretreatment 
failed to inhibit the phosphorylation of SAPK/JNK following IL-1β treatment at both 5 and 10 
minutes. Taken together, these results suggest that resolvins modulate alveolar epithelial activation 
through a decrease in p38 and ERK 1/2 MAPKs.  
 
Discussion 
IL-1β is known to be one of the earliest and most bioactive cytokines secreted following 
acute injury [3]. Release of this potent proinflammatory molecule causes up regulation of 
proinflammatory pathways on epithelial and endothelial cells leading to cytokine secretion 
[6,34,39]. This cytokine secretion is key to propagating the inflammatory signal beyond the 
airways and into the vasculature. We therefore investigated the effect of resolvins to curb 
inflammatory cytokine IL-6 and chemokine IL-8/CXCL8. These mediators, through paracrine, and 
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autocrine signaling play a key role in persistence of the inflammatory phenotype [40-44]. We 
demonstrated the ability of resolvins to significantly curb the secretion of these proinflammatory 
cytokines. Further, we show that this decrease in cytokines by AT-RvD1 also correlated with a 
decrease in the expression of intercellular adhesion molecule-1 (ICAM-1). Once secreted into the 
extracellular milieu these inflammatory cytokines serve to upregulate important adhesion 
molecules that are used by migrating leukocytes to enter into the injured tissue and further prolong 
the inflammatory cycle [45]. These leukocytes such as neutrophils and monocytes are rich in 
proinflammatory mediators and add to the multifunctional inflammatory sequence that is not easily 
overcome naturally in inflammatory lung diseases. Our results tether AT-RvD1 to reduced 
proinflammatory molecules; however, we did not know the functional consequences of this 
reduced pro-inflammatory profile.  
Since administration of AT-RvD1 significantly decreased the factors that play a role in 
monocyte recruitment such as adhesion molecule expression and cytokine secretion, we wanted to 
investigate IL-1β-induced alveolar epithelial cell-leukocyte interaction through adhesion. 
Monocytes and neutrophils serve as key first responders to the site of injury and can also be 
implicated as culprits in the overactive immune response. Inflammatory monocytes in the presence 
of inflammatory mediators such IL-1β, migrate into the tissue and differentiate into macrophages 
and ultimately foam cells in early injury. These differentiated monocytes have a much longer 
lifespan than infiltrating neutrophils and serve to consistently reinvent the proinflammatory signal 
in uncontrolled inflammation seen in ALI. Therefore, we wanted to investigate the effect of 
resolvins on the attachment to an IL-1β stimulated alveolar epithelium, citing the fact that IL-1β 
induces leukocyte attachment through adhesion molecule upregulation.  In line with its effects on 
cytokine secretion and ICAM-1 expression, AT-RvD1 significantly diminished the effect of IL-1β 
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to induce alveolar epithelial cell and monocyte adhesion. This correlates with previous reports that 
demonstrate resolvins as key mediators of leukocyte influx and barrier resistance.  By our hands, 
however, we were not able to show an improvement in IL-1β-mediated alveolar epithelial barrier 
dysfunction with resolvin treatment. 
 MAP kinases are key molecules found in a variety of cells involved in the immune 
response. While different MAP kinases are important in different cells, the three predominant map 
kinases (p38, ERK, and SAPK/JNK) have all been shown to play a role in epithelial inflammatory 
signaling. AT-RvD1 treatment in accordance with previously reported effects of other resolvins 
on MAPKs showed a significant decrease in p38 and ERK phosphorylation and subsequent 
activation. However, we did not observe a change in SAPK/JNK signaling. P38 and ERK have 
been shown to be responsible for the production of proinflammatory cytokines following IL-1β 
stimulation. They have also been shown to be involved in adhesion molecule expression. Our 
results with resolvin pretreatment suggest a protective mechanism for resolvins through regulation 
of MAP kinase activity. 
Inflammatory lung disorders such as cystic fibrosis or ALI feature significantly enhanced 
levels of proinflammatory cytokines as well as aggressive infiltration of leukocytes into the injured 
tissue. While alveolar macrophages play a key role in the secretion of early mediators such as IL-
1β, the alveolar epithelium is an important source of inflammatory mediators as well and a key 
site of immune cell tissue interaction following injury. Secretion and binding of IL-1β leads to 
barrier dysfunction, cytokine/chemokine secretion, and barrier dysfunction. Omega-3 (ω-3) free 
fatty acids have shown beneficial effects in vitro at curbing the immune response. Ω-3 derivatives 
termed ‘resolution-phase interaction products’ have also been demonstrated to curb the 
inflammatory phenotype seen in diseases such as COPD and aspiration pneumonia-induced ALI. 
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In this article, we demonstrate for the first time the protective effects of aspirin-triggered resolvin 
D1 (AT-RvD1) in diminishing the inflammatory phenotype of these cells following IL-1β 
stimulation. Together, this report supports previous studies that show that resolvins are potent 
potential therapeutic for inflammation seen in ALI. More importantly, these experiments 
demonstrate a novel role of AT-RvD1 in the inhibition of IL-1β-induced alveolar epithelial cell 
activation.  
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Figures 
 
Figure 2.1: H2O2 and ATP Treatment Results in Enhanced IL-1β Secretion in THP-1 
Macrophages. In order to reconstruct a physiologically relevant model of hyperoxia induced 
macrophage secretion, primed THP-1 macrophages were treated with ATP (5µM), H2O2(10mM) 
or combination of both ATP and THP1 for 1hr. IL-1β released into the cell culture supernatant 
was analyzed. One way ANOVA was used with a tukey post-hoc test, where a p-value <.05 was 
deemed statistically significant. Significance: * = p< .05 , ** = p< .01, *** = p< .001, vs no 
treatment control. 
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Figure 2.2: Omega-3 Treatment results in decreased hyperoxia induced IL-1β secretion in 
THP1 macrophages. In order to assess the therapeutic effects of omega-3 fatty acids DHA and 
EPA as well as resolvin metabolites on IL-1β secretion, primed THP-1 macrophages were treated 
with ATP (5µM), H2O2(10mM) or combination of both ATP in the presence or absence of EPA, 
DHA, RvD1 and AT-RvD1 at indicated doses for 1hr. IL-1β release into the cell culture 
supernatant was analyzed. One way ANOVA was used with a tukey post-hoc test, where a p-value 
<.05 was deemed statistically significant. Significance: * = p< .05 , ** = p< .01, *** = p< .001, vs 
no treatment control. 
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Figure 2.3: Resolvin Treatment results in decreased hyperoxia caspase-1 activation in THP1 
macrophages. In order to assess the role of RvD1 and AT-RvD1 on IL-1β processing enzyme 
caspase-1, primed THP-1 macrophages were treated with ATP (5µM), H2O2(10mM) or 
combination of both ATP in the presence or absence of RvD1 and AT-RvD1 at indicated doses for 
1hr. Activated caspase-1 into the cell culture supernatant was analyzed by ELISA. One way 
ANOVA was used with a tukey post-hoc test, where a p-value <.05 was deemed statistically 
significant.  
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Figure 2.4: Resolvin Treatment results in decreased hyperoxia caspase-1 activation in THP1 
macrophages. In order to decipher whether resolvin mediated reduction in hyperoxia induced IL-
1β in macrophages leads to a change in epithelial cell activation, primed THP-1 macrophages were 
treated with ATP (5µM) + H2O2 (10mM) in the presence or absence of RvD1 (100nM) and AT-
RvD1 (100nM) )  at indicated doses for 1hr. Secretion of IL-8 into the cell culture supernatant was 
analyzed by ELISA. One way ANOVA was used with a tukey post-hoc test, where a p-value <.05 
was deemed statistically significant.  
 
 
 
 
 
60 
 
Figure 2.5: Aspirin-Triggered Resolvin D1 Attenuated IL-1β-induced Cytokine/Chemokine 
Secretion. A549 cells were seeded at a density of 0.5 x 106 million cells per well in 12 well plates. 
When cells reached confluence, they were then serum starved and treated with IL-1β (10 ng/mL) 
in the presence or absence of aspirin-triggered resolvin D1 (AT-RD1, 100 nM) for 6 hrs. Following 
treatment, cell culture supernatants were collected and the presence of (A) IL-8 and (B) IL-6 levels 
were analyzed by ELISA. A student t-test was used to determine statistical significance with p < 
0.05 being statistically significant. ND = Not detected, limit of detection 2 pg/mL. 
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Figure 2.6: Aspirin-Triggered Resolvin D1 Attenuate IL-1β-induced Intercellular Adhesion 
Molecule-1 Expression. A549 cells were seeded at a density of 0.5 x 106 million cells per well in 
12 well plates. When cells reached confluence, they were then serum starved and treated with IL-
1β (10 ng/mL) in the presence or absence of aspirin-triggered resolvin D1 (AT-RD1, 100 nM) for 
6 hrs. Following treatment, cells were lysed in Trizol and mRNA was extracted. Complimentary 
cDNA was produced and qPCR analysis was performed utilizing primers specific for ICAM-1. 
Statistical significance was determined using a standard student t-test with p < 0.05 being 
statistically significant. 
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Figure 2.7: Aspirin-Triggered Resolvin D1 Attenuated IL-1β-mediated leukocyte-epithelial 
cell adhesion. A549 cells were seeded in A) 12 well at a density of 0.75 x 106 or B) 96 well plates 
at a density of 0.1 x 106 cells per well. Following serum starvation the cells were treated with IL-
1β (10 ng/mL) in the presence or absence of aspirin-triggered Resolvin D1 (100 nM) for 6 hrs. 
Following IL-1β treatment, calcein AM loaded THP1 cells were co-incubated with the alveolar 
epithelial cells for 30 minutes. Unbound attached monocytes were washed away with media and 
leukocyte attachment was observed via (A) fluorescent microscopy and (B) quantified with a 
reading of mean fluorescence intensity at Ex: 495 Em: 515. Statistical significance was measured 
with a one-way ANOVA with p < 0.05 being statistically significant. 
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Figure 2.8: Aspirin-Triggered Resolvin D1 does not rescue barrier function in IL-1β-treated 
A549 cells. A549 cells were seeded in 8 well 8W1E ECIS arrays at a density of 5 x 104 cells/mL. 
When cells reached confluence, they were treated with IL-1β (10 ng/mL) in the presence or 
absence of AT-RD1 (100 nM). Barrier resistance was recorded over 48 hrs using ECIS. To 
eliminate variability; samples were treated, duplicated, and recorded 4 times at each time point. 
Significance was measured with a one-way ANOVA with p < 0.05 being statistically significant. 
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Figure 2.9: Resolvins regulate IL-1β-induced p38 and ERK 1/2 activity in alveolar epithelial 
cells. A549 cells were seeded at a density of 0.5 x 106 million cells per well in 12 well plates. When 
cells reached confluence, they were then serum starved and treated with IL-1β (10 ng/mL) in the 
presence or absence of aspirin-triggered resolvin D1 (AT-RvD1, 100 nM) for 6 hrs. Following 
treatment, cells were harvested and lysed with RIPA buffer. Western blot analysis was performed 
and the samples were probed for the presence of total and phosphorylated (A) p38 and (B) ERK 
1/2 MAPKs using enhanced chemiluminescence.  
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Figure 2.10: AT-RvD1 is a double edged sword that blunts macrophage and epithelial 
communication through reduced cytokine signaling. Hyperoxia exposure leads to an enhanced 
secretion of proinflammatory cytokines, with IL-1β being the most bioactive for ALI patients. IL-
1β Secretion results in alveolar epithelial cell activation which is hallmarked by enhanced barrier 
function, cytokine secretion, and adhesion molecule expression. We found that AT-RvD1 was able 
to interrupt the macrophage to alveolar communication through the blockage of IL-1β signaling. 
Upon treatment of alveolar epithelial cells with IL-1β, there was an increase in inflammatory 
activation, which was significantly attenuated with AT-RvD1 treatment.  
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Chapter 3: Hyperoxic Acute Lung Injury Resolution is 
Enhanced by Aspirin Triggered Resolvin D1 Treatment in vivo. 
 
Abstract 
Acute lung injury (ALI), which presents as acute respiratory failure, is a major clinical 
problem that requires aggressive care, and patients that require prolonged oxygen exposure are at 
risk to develop this disease. Although molecular determinants of ALI have been reported, the 
molecules involved in disease catabasis associated with oxygen toxicity have not been well 
studied. It has been reported that lung mucosa is rich in omega-3 fatty acid dicosahexanoic acid 
(DHA), which has anti-inflammatory properties. Aspirin triggered-resolvin D1 (AT-RvD1) is a 
potent proresolution metabolite of DHA which can curb the inflammatory effects in various 
acute injuries, yet the effect of AT-RvD1 on hyperoxic acute lung injury (HALI) or in the 
oxygen toxicity setting in general has not been investigated. The effects of AT-RvD1 in HALI 
were determined for the first time in 8-10 week old C57BL/6 mice which were exposed to 
hyperoxia (≥95% O2) for 48hrs. Mice were either given AT-RvD1 (100ng) in saline or a saline 
vehicle for 24hrs in normoxic (≈21% O2) conditions following hyperoxia. Lung tissue and 
bronchoalveolar lavage (BAL) fluid were collected for analysis associated with proinflammatory 
signaling and lung inflammation. AT-RvD1 treatment resulted in reduced oxidative stress, 
increased glutathione production and significantly decreased tissue inflammation. AT-RvD1 
treatment also significantly reduced the lung wet/dry ratio, protein in BAL fluid, and decreased 
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apoptotic and NFκB signaling. These results show that AT-RvD1 curbs oxygen induced lung 
edema, permeability, inflammation, and apoptosis and is thus an effective therapy for prolonged 
hyperoxic exposure in this murine model. 
 
Introduction 
Acute lung injury (ALI) is a major clinical problem that contributes to the death of 
greater than 70,000 people annually in the United States (1, 2). ALI is an acute respiratory 
syndrome hallmarked by a breakdown of the alveolar-capillary membrane barrier, lung edema 
formation, pulmonary epithelial cell death, and an acute inflammatory response. While the 
pathogenesis is heterogeneous, extensive studies  have not led to an effective treatment (3). 
Hyperoxic therapy remains the major form of supportive care for patients with decreased 
respiratory function such as those who suffer from ALI. However, prolonged hyperoxic exposure 
(greater than 65% O2), can lead to further exacerbation of lung symptoms and cause hyperoxic 
acute lung injury. Murine models of hyperoxia display similar symptoms and pathology to those 
seen in humans (4-8). Toxic concentrations of oxygen lead to generation of reactive oxygen 
species which lead to a redox imbalance and in turn causes alveolar flooding, inflammation, 
apoptosis and necrotic death of alveolar epithelial cells (9, 10). Excessive hyperoxemia also 
leads to upregulation of proinflammatory mediators such as IL-1β (11). It may also lead to 
activation of the apoptotic signaling cascades triggered by the enhanced expression of 
proapoptotic proteins of the BH3-only BCL-2 protein family (12, 13). While several laboratories, 
including our own, have previously reported the molecular determinants that may play a role in 
HALI development (11, 13-15), the process of lung resolution and repair has not been well 
studied, especially in the oxidant toxicity setting.  
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HALI is usually self-limiting and resolves with minimal fibrosis in comparison to other 
models of ALI (16, 17); however, the molecular mechanisms involved in tissue catabasis has not 
been elucidated. Polyunsaturated fatty acid (PUFA) supplements significantly improve 
circulating anti-inflammatory biomarkers, reduce inflammatory cytokine levels, and promote gas 
exchange in adolescent and adult lung injury patients (18, 19). The PUFAs generated following 
injury serve as key mediators of inflammation. Of these fatty acids, omega-3 derivatives, referred 
to as resolution phase interaction products (resolvins), have drawn considerable interest for their 
potential to resolve acute injury in various disease models (20-28). These lipid mediators are 
anti-inflammatory, promote tissue homeostasis, and help revert injured and inflamed tissue to a 
normal state. Resolvins, discovered in resolving inflammatory exudates in mice, are classically 
synthesized through a primarily lipoxygenase driven pathway. In the presence of aspirin, 
however, more stable and less enzymatically susceptible “aspirin-triggered” epimeric forms are 
generated through aspirin-induced cyclooxygenase-2 acetylation (21).  
Previous reports show anti-inflammatory and pro-resolving roles of Aspirin-Triggered 
Resolvin D1 (7S,8R,17R-trihydroxy-4Z,9E,11E,13Z,15E19Z-docosahexaenoic acid, AT-RvD1), 
in the reduction of other sterile injuries such as aspiration pneumonitis in mice (26, 27). 
However, oxidant stress as a result of this study was found to be very low and thus, the ability of 
AT-RvD1 to alleviate inflammation and injury resulting from oxygen toxicity has not been 
properly investigated. Therefore, in this study we investigated the effects of AT-RvD1 on the 
resolution of HALI. While 24 hour treatment with vehicle allowed for modest resolution, 
treatment with AT-RvD1 following hyperoxia exposure resulted in a significant increase in 
decreased oxidative stress, increased resolution of tissue inflammation, enhanced antioxidant 
production, enhanced clearance of cellular infiltration and reduction of edema formation and 
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alveolar protein leak. AT-RvD1 treatment also resulted in a marked decrease in pro-
inflammatory and apoptotic signaling. Thus results also suggest that AT-RvD1 enhances HALI 
resolution. 
 
Materials and Methods 
 
Animals 
The University of South Florida Institutional Animal Care and Use Committee approved 
the animal protocol. Six to eight-week-old C57BL/6 WT mice (Harlan Laboratories, 
Indianapolis, IN) were used to conduct all in vivo experiments. They were housed in isolated 
cages on an automatic 12-hr light to dark cycle at room temperature (25°C). Water and standard 
food were available ad libitum.  
 
Murine Hyperoxic Injury Resolution Model 
Lung injury was induced using a murine hyperoxia model as previously described (9, 29). 
Mice, in cages, were placed in an airtight chamber (70 x 50 x 50 cm) and exposed to hyperoxic 
conditions (95-100% O2) for 48 hrs, sufficient to induce moderate to severe acute lung injury 
(30). An oxygen regulator was used to monitor and maintain the chamber’s atmospheric 
conditions (BioSpherix, NY, USA). To assess the impacts of AT-RvD1 on hyperoxic lung injury 
resolution, mice were kept under normoxic conditions (21% O2) following hyperoxic exposure 
and given either AT-RvD1 (Fig. 3.1A, 7S,8R,17R-trihydroxy-4Z,9E,11E,13Z,15E19Z-
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docosahexaenoic acid, 0.5-0.05μg, 95% purity, no LPS was detected, Caymen Chemicals, Ann 
Arbor, MI) or vehicle (1% ethanol in saline) to serve as an indicator of normal injury resolution 
(control group). 100 µl of AT-RvD1 or saline was injected via the i.v or i.p. route of 
administration. Mice were euthanized 24 hrs after treatment and tissue samples and 
bronchoalveolar lavage (BAL) fluid were collected in separate experiments. The experimental 
outline is shown in schematic form in fig. 3.1B 
 
Enzyme Linked Immunosorbant Assay (ELISA) 
Cytokines in BAL fluid were collected and analyzed as described previously (31). The 
levels of proinflammatory mediators IL-1β, TNF-α, IL-6 keratinocyte-derived chemokine (KC) 
and monocyte chemoattractant protein 1 (MCP-1) were measured by ELISA according to the 
manufacturer’s instructions (Affymetrix ebioscience, San Diego, CA). Levels of TNF-α 
following hyperoxia were not detectable in both AT-RvD1 and vehicle groups. Myeloperoxidase 
from lung tissue was also assessed via ELISA according to manufacturer’s instructions (R&D 
Systems, Minneapolis, MN) 
 
Immunohistochemical Staining on Lung Tissue Sections 
Immunohistochemical staining (IHC) was performed on paraffin embedded lung tissue 
sections as previously described and according to the manufacturer’s instructions (32). Lung 
tissue sections were incubated with 20 μg/ml of proteinase K for 40 minutes at 37°C following 
deparaffinization. Tissue sections were then blocked with 3% hydrogen peroxide in PBS 
followed by incubation with goat anti-mouse active caspase-3 antibody (Abcam, Cambridge, 
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England, UK) overnight at 4°C. The sections were subsequently incubated with anti-rabbit 
horseradish peroxidase conjugate for 60 min at 37°C. Images were taken to assess cellular 
apoptosis following the addition of 3, 3′-diaminobenzidine. 
 
Glutathione 
Following euthanization, lung tissues of mice from each group were harvested (N=4). 
Total GSH was measured using GSH detection kit from Enzo Life Sciences (Farmingdale, NY) 
as previously described (33). 
 
mRNA Quantification 
Following euthanasia, lung tissue samples were collected and flash frozen in liquid 
nitrogen as previously described (30). Total mRNA was harvested from lung tissues and 
converted to cDNA using the iScript cDNA Syntehsis Kit (Bio-Rad, Hercules, CA). The 
following primers were used and synthesized through Integrative DNA Technologies: Nrf2 
forward 5′-TCTCCTCGCTGGAAAAAGAA-3′ Nrf2 reverse 5′-
AATGTGCTGGCTGTGCTTTA-3′; 18s forward 5´TTGACGGAAGGGCACCACCAG 3´ and 
18s reverse: 5´CTCCTTAATGTCACGCACGATTTC 3´). Quantitative RT-PCR was performed 
as previously described (34). 
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Preparation of Protein Extract  
Following euthanasia, lung tissue samples were collected and flash frozen in liquid 
nitrogen as previously described (30).  The protein extraction samples were thawed and 
homogenized in protein extraction buffer (20 mM, 125 Tris HCl, pH 7.4, 150 mM NaCl, 0.5% 
Triton X-100) supplemented with phosphatase and protease inhibitor cocktail (Sigma Aldrich, 
St. Louis, MO). Samples were homogenized on ice for 15 seconds and then sonicated. Samples 
were centrifuged at 12,000 rpms for 15 minutes at 4°C to extract protein from the sample after 
two freeze thaw cycles. Supernatants containing protein were collected, quantified, aliquoted and 
stored for future use. For NFκB analysis, the nuclear extractions were prepared utilizing the NE-
PER Nuclear and Cytoplasmic Extraction (Thermo-Scientific, Rockford, IL) according to 
manufacturer’s instructions. 
 
Western Blot Analysis 
Lung protein was extracted from tissue using the aforementioned methods. Samples were 
mixed with lamelli buffer, denatured (95°C for 5 minutes), and loaded (40-50 μg) onto a 10% 
SDS-PAGE gel prior to gel electrophoresis. Once the gels were completed, they were transferred 
onto a PVDF membrane (Thermoscientific, Rockford, IL) using the Mini-Protean apparatus 
(Bio-Rad, Hercules, CA). Membranes were then blocked in 5% non-fat dry milk for 1 hr and 
probed at 4°C overnight for antibodies directed against mouse phosphor-NFκB (p65 subunit), 
total NFκB (p65 subunit) in the nuclear fraction and phosphor-BAD, total BAD, BIM, phosphor-
p38, total p38, phosphor-p44/42, total p44/42, phosphor-SAPK/JNK, total SAPK/JNK, and 
active caspase-3 in lung lysate overnight. Membranes were probed with anti-rabbit secondary 
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antibody conjugated to HRP (Jackson ImmunoResearch Laboratories, West Grove, PA) 
following overnight incubation. Protein expression was detected using enhanced 
chemiluminescent Western blotting substrate (Thermo Scientific-Pierce, Rockford, IL) following 
secondary antibody exposure. All primary antibodies were purchased from Cell Signaling 
Technology (Danvers, MA) with the exception of active-caspase-3 (Abcam, Cambridge, 
England, UK). 
 
Lung Mechanics Analysis 
In a separate experiment, mice were anesthetized with ketamine-xylazine and placed on a 
small rodent mechanical ventilator and respiratory mechanics apparatus (SCIREQ, Montreal, 
Canada). The lung resistance of mice in each group (n = ≥8 in each group) was measured 
following ventilation. 
 
Statistical Analysis 
Statistical analysis was performed using the Graphpad Prism software (GraphPad 
Software, Inc. San Diego, CA). Comparison of samples between two groups was completed 
using a standard Student t-test. Comparison of samples in three or more groups was calculated 
using a one-way ANOVA with a Tukey post-hoc test to measure significance between groups. P-
values for all tests were calculated and labeled where significant. A p-value < 0.05 was 
considered significant and all t-tests were two-tailed. 
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Results 
 
AT-RvD1 Treatment Following Hyperoxic Injury Leads to Decrease Lung 
Resistance and Oxidative Stress 
Oxidative stress is the key insult of the HALI model and thus the ability of AT-RvD1 to 
resolve oxidative stress in lung tissue warrants investigation. Lipid peroxidation is a well-
documented indicator of oxidative stress (35-37). To test the ability of AT-RvD1 to reduce lipid 
peroxidation following hyperoxic injury, C57/BL6 mice were given AT-RvD1 (0.5-0.05µg) 
following 48 hr hyperoxia exposure. BAL fluid was collected and a TBARs assay was performed 
(Fig. 3.1C). Results reveal that AT-RvD1 treatment following hyperoxic injury leads to a greater 
than 75% decrease in lipid peroxidation as measured with the TBARs assay, in comparison to the 
vehicle group, which only showed a 25% decrease in lipid peroxidation. These results also 
suggest that AT-RvD1 provides significantly enhanced resolution of oxidative stress following 
HALI at an optimal dose of 0.1µg. Antioxidant imbalance is a well-documented result of 
oxidative stress (33, 38-43). Antioxidant-oxidant imbalance leads to antioxidant depletion and 
proinflammatory reactive oxidant-antioxidant complexes (36, 44-47). Our results reveal that 
mice treated with AT-RvD1 have significantly higher glutathione in lung tissues as well as 
significantly enhanced expression of antioxidant transcriptional regulator Nrf2 (Fig 3.10). 
Previous reports point to increased lung resistance as a result of oxidative stress (38, 48, 49). To 
further assess the functional contributions of AT-RvD1 (0.2-0.05µg) to hyperoxia-induced 
impairment of lung mechanics, lung resistance was measured using the SCIREQ flexiVent 
apparatus (Fig. 3.1D). Surprisingly, saline treatment resulted in a small increase in lung 
resistance following hyperoxia exposure; however, this increase was not statistically significant. 
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This phenomenon was curtailed with AT-RvD1 treatment following injury. AT-RvD1 treatment 
resulted in significantly reduced lung resistance in comparison to both the hyperoxia and the 
hyperoxia followed by vehicle treatment groups. The decreased lung resistance in response to 
AT-RvD1 treatment points to improved resolution of HALI.  
 
AT-RvD1 Treatment Following Injury leads to Decreased Hyperoxia-Induced 
Leukocyte Infiltration 
Previous reports have alluded to the increased airway resistance as a key indicator airway 
inflammation and an increase in inflammatory cell infiltrate (50-52). Recruitment of leukocytes 
to the injured area is a key hallmark of HALI, and reduction of this infiltration marks a key event 
in injury resolution. C57/BL6 mice were given AT-RvD1 (0.1 µg, I.V.) following 48 hr 
hyperoxia exposure to determine the capacity of AT-RvD1 to reduce leukocyte infiltration 
following hyperoxic injury. The leukocyte accumulation in the BAL fluid was analyzed using 
total and differential cell counts (Fig. 3.2). Images were taken of BAL fluid cells that were 
cytospun onto microscope slides and differentially stained (Fig. 3.3A-E). Results revealed that 
mice treated with AT-RvD1 had a three-fold decrease of total cells in the BAL fluid compared to 
mice treated with the vehicle (Fig. 3.2A). Differential counts of leukocytes revealed that both 
macrophages and neutrophils were significantly decreased in the AT-RvD1 group, with a greater 
than 10-fold decrease in neutrophil accumulation (Fig 3.2B, 3.2C, and black arrows in Fig 3.3A-
E). AT-RvD1-treated mice show a significant decrease in comparison to mice treated with 
vehicle following the injury in neutrophil percentage (< 3%) and a similarly significant increase 
in macrophage percentage (> 97%) among leukocyte subsets in BAL fluid (Fig. 3.2D). Results 
further show that KC, a neutrophil chemokine, is significantly decreased in the BAL of mice 
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treated with AT-RvD1 following injury (Fig. 3.3F). Myeloperoxidase, a peroxidase which is 
abundantly expressed in neutrophils, was significantly decreased in AT-RvD1-treated mice in 
comparison to vehicle control (Fig. 3.3G). Altogether, results indicate that AT-RvD1 treatment 
following hyperoxic injury significantly reduces accumulation of leukocytes into the injured 
area, especially neutrophils. 
 
AT-RvD1 Attenuates Hyperoxia-Induced Lung Inflammation and Permeability 
Influx of inflammatory cells is a hallmark of HALI and an indicator lung inflammation 
(1). It was hypothesized that AT-RvD1 treatment would resolve hyperoxia-induced lung 
inflammation, since mice treated with AT-RvD1 post hyperoxic injury demonstrated reduced 
lipid peroxidation and showed reduced leukocytes in BAL fluids. Analysis of tissue histology, 
which is a direct measure of lung inflammation, revealed that AT-RvD1 treatment led to a visible 
decrease in alveolar thickening, congestion, and alveolar immune cell infiltration in comparison 
to mice treated with vehicle alone (Fig. 3.4A-E). Pathological severity scoring showed a small 
improvement in tissue inflammation following 24 hr room air treatment; however, this 
improvement was not significant. More importantly, administration of AT-RvD1 following 
injury led to a significant improvement in pathological severity in comparison to the groups that 
were exposed to hyperoxia alone and hyperoxia followed by saline treatments (Fig. 3.4F). To 
further confirm the effects of AT-RvD1 treatment, lung edema and alveolar leak were examined 
by the wet to dry ratio and BAL protein analysis, respectively (Fig. 3.5). AT-RvD1-treated mice 
experienced a significant decrease in both lung wet-to-dry ratio and BAL protein levels 
following hyperoxia. This reduction in lung edema by AT-RvD1 was further confirmed by a 
decrease in dye extravasation into both the serum and the BAL fluid. (Fig. 3.6). Altogether, these 
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results highlight AT-RvD1’s role in improved tissue histology, permeability reduction, and 
prevention of further lung damage following injury.  
 
AT-RvD1 Regulates Hyperoxia-Induced Inflammatory Mediator Production 
The secretion of inflammatory mediators disrupts the immune-repressed alveolar state of 
resident macrophages and epithelial cells. In vitro and in vivo reports from our laboratory 
demonstrate that one of these mediators, Interleukin-1β (IL-1β), plays an important role in the 
inflammatory phenotype seen in the lung following hyperoxic exposure (11, 14, 30). Therefore, 
the influence of AT-RvD1 treatment on IL-1β secretion post-hyperoxic exposure was analyzed. 
In comparison to mice treated with vehicle, AT-RvD1 treatment significantly decreased IL-1β 
protein expression and secretion (Fig. 3.7A). Early cytokines released following injury, such as 
IL-6 and MCP-1, show a similar decrease with AT-RvD1 treatment (Fig. 3.7B & 3.7C). To 
further understand the mechanism of AT-RvD1 mediated reduction of hyperoxia-induced IL-1β 
expression, the activity of transcriptional regulator NFκB was analyzed. Lung tissue analysis 
reveals a decrease in NFκB activity with AT-RvD1 treatment compared to mice treated with 
vehicle alone, as measured by the phosphorylation of the nuclear NFκB p65 subunit (Fig. 3.7D). 
Mitogen activated protein kinases (MAPKs) are critical mediators for the activation of 
transcription factors, such as NFκB, that lead to cytokine processing following inflammatory 
stimuli. AT-RvD1 treatment resulted in an overall decrease in phosphorylation of MAPK p38 
(Fig. 3.7E); however, no changes in the phosphorylation of p44/42 and SAPK/JNK were 
detected (Fig. 3.8). These data demonstrate that AT-RvD1 treatment following hyperoxic 
exposure results in enhanced resolution of proinflammatory cytokine secretion and the reduction 
of proinflammatory signaling molecule activity 
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AT-RvD1 Treatment Following Injury Results in Decreased Hyperoxia-Associated 
Apoptotic Markers in Lung Tissue 
Hyperoxia treatment leads to increased cellular apoptosis in lung tissue (9-11, 30).  
Caspase-3 is a well-documented indicator of cellular apoptosis (53-55). Caspase-3 activity was 
assessed in lung tissue sections and whole lung homogenates via IHC and Western blot, 
respectively, to further assess cellular apoptosis. The results demonstrated a decreased presence 
of active caspase-3 in lung sections and protein extracts prepared from mice given AT-RvD1 
versus those given vehicle following hyperoxic exposure (Fig. 3.9 A-D). Proteins of the pro-
apoptotic BCL-2 family (BH3-only proteins) regulate apoptosis through interaction and 
inhibition of pro-survival molecules. Expression and activation of BH3-only proteins are 
important hyperoxia-induced signaling events that lead to epithelial cell death in ALI (8, 13).  
Phosphorylation of BH3-only protein BAD abolishes its pro-apoptotic activity. To confirm AT-
RvD1’s capability to reduce hyperoxia injury-induced apoptotic markers such as BAD, 
phosphorylation of BAD was analyzed from each sample. AT-RvD1 treatment, in comparison to 
vehicle control, resulted in increased phosphorylation of BAD in mice following hyperoxia 
exposure (Fig. 3.9 E). No significant change in total BAD was observed between AT-RvD1 and 
the vehicle-treated groups. BH3-only protein BIM also demonstrated reduced protein expression 
in mice given AT-RvD1 following hyperoxic injury in comparison to vehicle control (Fig. 3.9 
F). These results suggest that AT-RvD1 treatment results in decreased apoptotic activity through 
suppression of BH3-only protein expression and signaling. These results suggest further 
attenuation of hyperoxia-induced apoptotic signaling by AT-RvD1 treatment. 
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Discussion 
Hyperoxic therapy is a key component of supportive care for patients suffering from 
reduced respiratory function (56). Prolonged exposure of high concentrations of hyperoxia can 
lead to the generation of reactive oxygen species which can lead to hyperoxic acute lung injury 
(HALI) which at times presents as acute respiratory distress syndrome(57). Injury resulting from 
hyperoxic stress leads to decreased lung biomechanics, increased alveolar permeability, lung 
edema, and inflammation (30, 58). Free radical generation may also result in increased apoptotic 
signaling(59). While our laboratory as well as others have sought to dissect the molecular 
determinants associated with hyperoxic acute lung injury (3, 60), the molecular determinants 
involved in the restoration of innate tissue homeostasis and resolution of hyperoxic injury have 
not been clearly defined. In this study, we hypothesized that the pro-resolution mediator Aspirin 
Triggered-Resolvin D1 can enhance resolution of hyperoxic lung injury through decreased 
oxidative stress, lung resistance, permeability, inflammation and apoptotic marker expression 
(30, 61-63). Previous reports have demonstrated uniform animal death of mice exposed to 72-96 
hours of 95% hyperoxia (6, 64), because of this we chose to investigate at the 48 hr time point 
where moderate HALI pathology occurs and resolution after 24 hrs of injury can be investigated. 
In studying resolution, the hyperoxic model has its advantages as natural resolution takes place 
with mild scarring without fibrotic development (16, 17). Hyperoxia-induced reactive oxygen 
species generation contributes to enhanced lipid peroxidation and subsequent cellular injury (42, 
55, 65, 66).   Our laboratory and others have shown that hyperoxia overexposure results in the 
hyperactivation and ungoverned recruitment of proinflammatory leukocytes which include 
neutrophils and monocytes (8, 11, 30). In the latter stages of injury, the production of 
inflammatory mediators and reactive species by these cells contributes to a toxic alveolar 
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environment and further damage of healthy tissue. Results from this study demonstrate that AT-
RvD1 treatment following injury shows reduced lipid peroxidation, a key indicator of oxidative 
stress, in comparison to both hyperoxia and hyperoxia followed by vehicle treatment. For the 
first time, we show that lipid peroxidation is reduced with AT-RvD1 treatment.  It has been 
previously discussed that diet rich in docosahexaenoic acid, precursor of AT-RvD1, curbs 
oxidative stress and lipid peroxidation in rats following traumatic brain injury (67, 68). Our 
results further affirm these findings and point to AT-RvD1 as a key DHA metabolite in the 
reduction of oxidative stress following injury. DHA treatment has also been associated with 
increased antioxidant properties (69), however the effects of AT-RvD1 on redox signaling has 
not been studied. Our results reveal increased GSH and Nrf2 expression with AT-RvD1 
treatment. GSH supplementation has been demonstrated previously to enhance resolution of 
hyperoxic injury and is a major marker of oxidant antioxidant imbalance (33). Nrf2, a master 
regulator of antioxidant gene expression, has also been demonstrated to be important in 
resolution of hyperoxia induced acute lung injury through GSH regulation (33, 34, 40). Since 
previous reports of AT-RvD1’s beneficial action on acute injury are not a result of oxidative 
stress (27) and the hyperoxia model is based on injury as a result of oxidative stress, our finding 
that antioxidants such as GSH and regulators such as Nrf2 are enhanced is of great significance 
and represents a key next step of investigation as to how AT-RvD1 can combat oxidative stress. 
More specifically, this paper provides a platform and basis to assess in the future whether 
increased antioxidant machinery generated by AT-RvD1combats the antioxidant depletion and 
subsequent redox imbalance caused by hyperoxia (38, 42, 45) and whether or not AT-RvD1 be 
used as a therapeutic agent to increase antioxidant machinery and improve the effects of oxygen 
therapy. 
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Hyperoxic injury results in increased lung stiffening, inflammation and permeability (8, 
48, 56, 58, 70). Whether or not AT-RvD1 could curb these hallmarks of hyperoxic lung injury 
needed to be investigated. AT-RvD1 treatment following injury resulted in a significant decrease 
in lung resistance. Lung static compliance was also improved with AT-RvD1 treatment in 
comparison to hyperoxia alone; however, it was not significantly different than vehicle treatment 
alone during the resolution recovery period (data not shown). These findings suggest that AT-
RvD1 can alleviate lung stiffening and improve respiratory mechanics following hyperoxic 
injury. This is important as decreased respiratory function, in particular through increased airway 
resistance, is associated with fibrotic development (71) Results of this study demonstrated that 
treatment with AT-RvD1 following injury resulted in a much more significant reduction of 
leukocytes and tissue inflammation in the 24 hr injury resolution phase than the vehicle control. 
BAL fluid collection revealed decreased neutrophil counts in mice treated with AT-RvD1 
following injury in comparison with hyperoxia and vehicle control. Reduced neutrophil 
accumulation in BAL following injury may be a result of decreased expression and secretion of 
neutrophil chemoattractants such as KC. Further, peroxidase enzyme myeloperoxidase (MPO) 
was also reduced with AT-RvD1 treatment in comparison to vehicle treatment groups. Reduced 
KC and MPO have been extensively associated with reduced neutrophilia and tissue 
inflammation (72-79). Treatment with AT-RvD1 following hyperoxic injury also restored 
normal leukocyte population as the macrophage population in the BAL was increased by 17% in 
comparison to vehicle control, and the neutrophil population was reduced to 3% in comparison 
to 20% for the vehicle control. These results point to the ability of AT-RvD1 to decrease 
leukocyte inflammation and restore the leukocyte imbalance due to hyperoxic injury; however 
whether this is attributed to decreased oxidant stress and an enhanced antioxidant profile was not 
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thoroughly investigated. In future studies we aim to identify the link between the enhanced 
antioxidant activity stimulated by AT-RvD1 and the reduced inflammatory phenotype shown 
following AT-RvD1 treatment. 
Leukocyte infiltration is a prime indicator of inflammation which is a key hallmark of 
HALI and ungoverned regulation of inflammation results in downstream fibrotic development 
(80). Hyperoxic injury and cell damage leads to the release of proinflammatory cytokines such as 
IL-1β (11, 81, 82), which has been shown to be the most bioactive cytokine in lung injury 
patients (83). This laboratory has demonstrated that decreased IL-1β secretion results in 
improved lung pathology following hyperoxia challenge (11, 30). The results of this paper reveal 
that AT-RvD1 versus control treatment results in decreased expression of pro-IL-1β. 
Furthermore, IL-1β secretion is decreased following hyperoxia in mice given AT-RvD1 versus 
vehicle treatment. IL-1β, as one of the early cytokines secreted by alveolar macrophages 
contributes to hypercytokinemia following injury (83, 84). Thus it was hypothesized that with 
AT-RvD1 treatment would also result in a decrease of other proinflammatory cytokines. 
Analysis of proinflammatory cytokines, IL-6, KC, and MCP-1, in BAL revealed a similar 
decrease in mice given AT-RvD1 following hyperoxia exposure in comparison to vehicle 
treatment. While numerous reports from our laboratory have touched on the proteolytic 
processing of pro-IL-1β that is needed for activity (11, 14, 30), interestingly we found decreased 
expression of IL-1β in its pro-form which suggested  that AT-RvD1 treatment resulted in 
reduced transcriptional activity, leading to reduced IL-1β expression. Previous reports have 
linked the AT-RvD1 receptor, formyl peptide receptor 2 (FPR2/ALX) with decreased activity of 
proinflammatory transcription regulator, NF-κB (28). NF-κB and mitogen-activated protein 
kinases (MAPKs) are important proinflammatory transcription regulators responsible for the 
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activation of proinflammatory genes associated with the production of cytokines, adhesion 
molecules, and epithelial cell junction destabilization (85-88). These downstream products of 
NF-κB and MAPK activity contribute to the propagation of the proinflammatory cascade. 
Investigation into AT-RvD1’s effect on NF-κB activity following hyperoxia exposure revealed a 
significant decrease in phosphorylation of NF-κB following AT-RvD1 in comparison to vehicle 
control treatment. Phosphorylation of NF-κB is a key signaling event involved in the 
transcriptional activity of this molecule. Therefore, these results demonstrate that AT-RvD1 
treatment significantly impairs NF-κB activation. Similar effects are seen in p38 MAPk 
activation; however, the phosphorylation of the SAPK/JNK and p44/42 MAPks was not altered 
with AT-RvD1 treatment. Data obtained from this study further demonstrates that AT-RvD1 
versus control significantly resolves hyperoxia-induced inflammatory signaling and subsequent 
cytokine secretion. The role of FPR2/ALX in this AT-RvD1 mediated attenuation of hyperoxia 
induced inflammatory signaling still needs to be investigated in future studies. 
The alveolar capillary-barrier plays an important homeostatic role in the regulation of 
immune cell infiltration (1-3, 56). However, powerful inflammatory stimuli, such as hyperoxia, 
cause deterioration and remodeling of this barrier, which leads to aberrant and overactive 
inflammatory signaling (11, 56). Re-establishment of this barrier and decreased permeability are 
key steps in HALI resolution.  AT-RvD1 treatment following hyperoxia exposure demonstrates a 
significant decrease in both the lung wet to dry ratio and alveolar protein content in comparison 
to vehicle control. Further, AT-RvD1 treatment also demonstrates reduced epithelial and 
vascular permeability. Altogether, these results suggest that treatment of following injury 
reduces pulmonary edema and lung permeability. More importantly, these results suggest that 
AT-RvD1 significantly enhances barrier integrity during the resolution phase of hyperoxic 
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injury. Because inflammatory cytokines contribute to hyperoxia-induced alveolar permeability 
and barrier dysfunction, the ability of AT-RvD1 to suppress cytokine secretion may also 
contribute to the enhanced barrier integrity seen in this study. Tissue histology following AT-
RvD1 administration was assessed since the build-up of edema fluid that ensues from the 
compromised alveolar capillary barrier can lead to further activation of the alveolar epithelium, 
endothelium, and macrophages (2).  Pathological severity scoring from lung tissue sections 
further illustrated the pro-resolution effects of AT-RvD1 versus the control as tissue sections 
obtained from mice revealed improved tissue histology in areas of alveolar thickening, leukocyte 
infiltration, and decreased alveolar congestion. Changes in alveolar hemorrhage were not 
witnessed in these sections. Along with the improvement in permeability and decreased 
pathological severity scoring, mice administered AT-RvD1 during the resolution phase 
demonstrated less lung resistance and thus improved respiratory tract airflow. Taken together, 
these results suggest that AT-RvD1 significantly improves recovery time from injury. Results 
from this study demonstrate significant suppression of the ALI pathological severity. More 
importantly, our results suggest that AT-RvD1 may be acting on multiple protective pathways, 
which may point to the remarkable recovery seen in these mice treated with AT-RvD1. 
Apoptotic cell death of alveolar epithelial cells is a previously described result of 
hyperoxic insult (6). Cellular fragments, inactivated surfactant, and cellular contents from 
apoptotic cells result in further secretion of noxious stimuli into the pulmonary milieu (56). 
Previous reports from our laboratories have shown that BH3-only proteins play a role hyperoxia-
induced apoptotic signaling (8, 13). BAD is a pro-apoptotic family member of the BH3-only 
protein faction of the Bcl-2 family. Found primarily in the cytosol, BAD interacts with anti-
apoptotic proteins in order to prevent their mechanism of inhibition of apoptosis. 
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Phosphorylation of BAD leads to inactivation and allows the pro-survival function of anti-
apoptotic members of the Bcl-2 family (apoptosis). Results from this study show that treatment 
with AT-RvD1 versus the vehicle control significantly increased phosphorylation of BAD. More 
importantly, these results suggest for the first time that AT-RvD1 may affect the apoptotic 
signaling pathway through regulation of the proapoptotic BH3-only protein signaling cascade. 
Expression of fellow pro-apoptotic protein BIM, showed a reduction in protein expression with 
AT-RvD1 treatment following hyperoxic injury in comparison to vehicle controls. Caspase-3 
activation was measured to confirm the resulting decreased apoptosis. IHC staining showed an 
intense staining, localizing active caspase-3 expression mostly to the lung epithelial cells 
(bronchiolar and some alveolar staining) in the vehicle treatment group; however, AT-RvD1 
treatment following injury resulted in a significantly decreased expression in active-caspase-3 
via two distinct methods. Strong staining in shown in the distal bronchiolar epithelial cells and to 
a lesser extent, the alveolar epithelium, which is consistent with previous reports regarding 
hyperoxia induced pro-apoptotic signaling (89, 90)  These results further support AT-RvD1’s 
capability to resolve hyperoxia-induced apoptotic signaling.  
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Figure 3.1: AT-RvD1 treatment following hyperoxic lung injury demonstrates improved 
lung mechanics and decreased oxidative stress. C57BL/6 mice were subjected to hyperoxia or 
normoxia exposure for 48 hrs followed by treatment with AT-RvD1 (Structure shown in panel 
A,) or saline vehicle for 24 hrs administered IV (Treatment outline shown in panel B). (C) In a 
separate experiment, lungs were harvested from each mouse and lipid peroxidation was 
measured via the thiobarbituric acid reactive substances assay. Prior to euthanasia, (D) Lung 
resistance was measured following each treatment using the flexiVent respiratory metrics 
apparatus (see methods). A one-way ANOVA, with a Tukey post-hoc test, was used to determine 
the results where a p-value of p < 0.05 was deemed statistically significant (N = 6 for each 
group). 
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Figure 3.2: AT-RvD1 treatment following hyperoxic injury reduces cells in BAL fluid and 
rescues leukocyte imbalance. C57BL/6 mice were subjected to normoxia or hyperoxia exposure 
for 48 hrs followed by treatment with AT-RvD1 (100 ng) or saline vehicle for 24 hrs in 
normoxia. An equal mixture of BAL fluid was collected and cytospun unto microscope slides for 
leukocyte analysis. Cytospin smears were stained via Diffquick stain. Total (A) and differential 
cell (B-C) count was performed. Analysis of the BAL macrophage and neutrophil percentage 
was also calculated (D). A one-way ANOVA, with a Tukey post-hoc test, was used to determine 
the results where a p-value of p < .05 was deemed statistically significant (n = 10 in each group). 
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Figure 3.3: AT-RvD1 treatment following hyperoxic injury enhanced clearance of cellular 
debris and cell infiltrate in BAL fluid. C57BL/6 mice were subjected to normoxia or hyperoxia 
exposure for 48 hrs followed by treatment with AT-RvD1 (100 ng) or saline vehicle for 24 hrs in 
normoxia (n = 6 for each group). An equal mixture of BAL fluid was collected and cytospun 
unto microscope slides for leukocyte analysis (A-E). Representative images for each group are 
shown (A-E). Original magnification: 100X. Neutrophils in BAL fluid are highlighted by black 
arrows. Murine neutrophilic chemokine KC from BAL fluid (F) as well as myeloperoxidase from 
lung homogenates (G) was also measured. A one-way ANOVA was used to determine the results 
where a p-value of p < 0.05 was deemed statistically significant (n = 10 in each group). 
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Figure 3.4: AT-RvD1 regulates hyperoxia enhances resolution of hyperoxia-induced tissue 
inflammation. C57BL/6 mice were subjected to normoxia or hyperoxia exposure for 48 hrs 
followed by treatment with AT-RvD1 (100 ng) or saline vehicle for 24 hrs in normoxia (n = 6 for 
each group) administered IV. Lung sections were obtained and stained with H&E to analyze lung 
histology (A-E). Original magnification: 40X. Representative images for each group are shown. 
(F) Four independent parameters (alveolar congestion, hemorrhage, leukocyte infiltration, and 
alveolar wall thickness) were scored and used to determine the acute lung injury severity score. 
These are the cumulative results of three independent experiments (n = 10 in each group). A one-
way ANOVA was used to determine the results where a p-value of p < .05 was deemed 
statistically significant.   
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Figure 3.5: AT-RvD1 treatment following hyperoxia demonstrates reduced pulmonary 
edema and permeability. C57BL/6 mice were subjected to normoxia or hyperoxia exposure for 
48 hrs followed by treatment with AT-RvD1 (100 ng) or saline vehicle for 24 hrs (n = 6 for each 
group) administered IV. (A-B) Following AT-RvD1 or vehicle treatment, lungs tissue was 
harvested and the weight of the “wet” lungs was measured. Lungs were placed in an oven at 
70°C and measured periodically until the measurement was constant (“dry weight”). The wet/dry 
ratio was measured for each group. (C-D) In a separate subset of animals (n = 6 for each group), 
BAL fluid was collected. Following AT-RvD1 or vehicle treatment and total protein in BAL 
fluid for each group was measured via BCA assay. A one-way ANOVA was used to determine 
the results where a p-value of p < .05 was deemed statistically significant.   
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Figure 3.6: AT-RvD1 blunts hyperoxia-induced alveolar permeability and pulmonary 
edema. C57BL/6 mice were subjected to normoxia or hyperoxia exposure for 48 hrs followed by 
treatment with AT-RvD1 (100 ng) or saline vehicle for 24 hrs (n = 6 for each group) 
administered IV. (A) Endothelial barrier integrity was determined via introduction of Evans Blue 
dye administered intravenously 30 minutes prior to the end of each treatment. Following 
euthanasia, quantification of Evans blue dye in the BALF was used to examine endothelial 
barrier integrity. In a separate experiment, (B) epithelial barrier integrity was assessed by 
analyzing the serum-to-BALF ratio of extravasated 3000MW FITC dextran, administered 
intratracheally 20 minutes prior to end of each treatment. A one-way ANOVA was used to 
determine the results where a p-value of p < .05 was deemed statistically significant.   
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Figure 3.7: AT-RvD1 treatment following injury attenuates hyperoxia-induced cytokine 
expression and secretion. C57BL/6 mice were subjected to normoxia or hyperoxia exposure for 
48 hrs followed by treatment with AT-RvD1 (100 ng) or saline vehicle for 24 hrs in normoxia (n 
= 6 per group). Following AT-RvD1 or vehicle treatment, BAL Fluid was collected from mice in 
each group. Enzyme linked immunosorbant assays were performed using BAL fluid to assess 
cytokine secretion of (A) IL-1β, (B) IL-6, and (C) MCP-1. In a separate experiment (n = 6 per 
group), total protein was extracted and used for western blot analysis of phosphorylation of (D) 
NFκB P65 subunit (in the nuclear fraction) and (E) p38 MAP Kinase. T = total, p = 
phosphorylated form of assayed proteins. Densitometry of each phosphorylated protein shown 
below the blot and is representative of three separate experiments. Representative blots of each 
group for each protein are shown. A one-way ANOVA (for each ELISA) or Student t-test (blot 
densitometry) was used to determine the results where a p-value of p < .05 was deemed 
statistically significant.  
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Figure 3.8: AT-RvD1 Treatment following injury does not result in enhanced P44/42 and 
SAPK/JNK MAP Kinase activity. C57BL/6 mice were subjected to normoxia or hyperoxia 
exposure for 48 hrs followed by treatment with AT-RvD1 (100 ng) or saline vehicle for 24 hrs (n 
= 6 for each group) administered IV. Following AT-RvD1 or vehicle treatment, lung tissue was 
collected from mice in each group. Total protein was extracted from harvested tissue and used to 
run for western blot analysis of the phosphorylation of (A) P44/42 (B) SAPK/JNK MAP kinases. 
T=total, p=phosphorylated form of assayed proteins. Densitometry of each phosphorylated 
protein shown below the blot and is representative of three separate experiments. Representative 
blots of each group for each protein are shown. Student test was used to analyze statistical 
significance, where a p-value of p < .05 was considered statistically significant.  
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Figure 3.9: AT-RvD1 decreases hyperoxia-induced pro-apoptotic protein expression. 
C57BL/6 mice subjected to hyperoxia treatment for 48 hrs followed by treatment with AT-RvD1 
(100 ng) or saline vehicle for 24 hrs (n = 4 for each group) administered IV. Following AT-
RvD1 or vehicle treatment, Lung tissues from each group were fixed in formalin and embedded 
in paraffin blocks. (A-C) IHC was performed on lung tissue sections to examine the expression 
of active caspase-3. Original magnification: 100X; insets, 200X. To further measure apoptotic 
markers, lung tissue homogenates were examined for the presence of (C) active-caspase-3, (D) 
phosphorylated and total BAD, and (E) BIM via Western blot. The densitometry of each protein 
is shown to right of its respective blot. Student test was used to analyze statistical significance, 
where a p-value of p < .05 was considered statistically significant. 
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Figure 3.10 AT-RvD1 treatment following injury leads to enhanced glutathione production 
and Nrf2 expression. C57BL/6 mice subjected to hyperoxia treatment for 48 hrs followed by 
treatment with AT-RvD1 (100 ng) or saline vehicle for 24 hrs (n = 4 for each group) 
administered IV. Following AT-RvD1 or vehicle treatment, lung tissue was collected from mice 
and in each group and divided into sections for assay screening. (A) Glutathione (GSH) detection 
assay was used to measure GSH levels. (B) After obtaining mRNA from lung tissue, qPCR 
analysis was perfumed to identify Nrf2 expression. Both assays are shown relative to room air 
controls. A one-way ANOVA (for each ELISA) or Student t-test (blot densitometry) was used to 
determine the results where a p-value of p < .05 was deemed statistically significant.  
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Chapter 4: Summary and Conclusions 
 
Summary   
Acute lung injury is a devastating respiratory syndrome featuring a progressive 
inflammatory cascade.  Attempts at treatment of this deadly disease have failed and mechanical 
ventilation at high fraction of inspired oxygen is currently the only useful form of supportive 
care. Prolonged exposure to high concentrations of oxygen results in the development of 
hyperoxia induced acute lung injury. Reactive oxygen species generated during this injury 
initiate a vicious and recurrent cycle of injury and death [1]. Prolonged exposure to hyperoxia 
dysregulates endogenous repair and resolution machinery, however sublethal and self-limiting 
time points of hyperoxia exposure has enabled us to examine key factors involved in injury 
resolution. 
 Poly unsaturated fatty acids already play a key role in the patient ICU setting as 
parenteral feeding with omega-3 fatty acids results in better patient outcomes [2,3]. However 
their role in the resolution of injury is not properly understood and has led to significant 
investigation in recent reports. By products of omega-3 fatty acids EPA and DHA, termed 
resolvins, have gained considerable acclaim for their ability to reduce proinflammatory cytokine 
secretion while promoting macrophage uptake of apoptotic neutrophils in various acute models 
of injury [4]. One of these products, AT-RvD1 was recently reported to be particularly important 
in the resolution of injury by acid inspiration, however as reported by eickmeier, the oxidative 
stress was relatively low and did not contribute to the examination of injury resolution by 
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resolvins [5]. Since our previous reports have detailed the effects of oxidant injury on alveolar 
permeability, inflammation and apoptosis [6-9], we chose to examine AT-RvD1 as a potential 
candidate molecule to alleviate the hyperoxia mediated ALI hallmarks. In vitro investigation 
revealed that AT-RvD1 significantly decreased oxidant induced macrophage secretion of 
proinflammatory mediator IL-1β. AT-RvD1’s was able to show significant attenuation of IL-1β 
at low nanomolar levels and was more potent than its RvD1 epimer as well as RvD2 in 
preliminary studies. More importantly we saw that AT-RvD1 treatment resulted in reduced 
macrophage related alveolar activation via reduction of IL-1β signaling. While a weakness of 
this study was that we did not use of IL-1β receptor activators in order to see if we can rescue the 
macrophage induced secretion of cytokines from alveolar epithelial cells, the use of an IL-1 
receptor antagonist, enables us to highlight that IL-1β related decrease does play a role in AT-
RvD1’s beneficial actions on both the macrophage and the alveolar epithelium. Further, the 
reports of IL-1β being the most bioactive cytokine in the lungs of acute lung injury patients 
serves to confirm our thoughts about the importance of this molecule [10]. 
In an effort to examine if direct IL-1β mediated stimulation and activation could be 
affected by AT-RvD1 treatment, alveolar epithelial cells were treated with recombinant IL-1β in 
the presence or absence AT-RvD1. Results demonstrated not only a reduction in signaling but 
also reduced function. Not only was there reduced cytokine expression and adhesion with AT-
RvD1 treatment, but epithelial to leukocyte adhesion was also hampered as a result of this 
effects. The ability of AT-RvD1 to hamper leukocyte adhesion is reported for the first time and 
is quite significant as leukocyte influx into the alveolar space is consistent with injury 
progression and outcome [1,11,12].   
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Resolvins are well documented molecules involved in activation of proresolution 
machinery. Oxygen is also an important and unavoidable form of supportive care, however the 
effects of prolonged oxygen exposure are significant. Therefore, we wanted to examine how 
resolvins, specifically AT-RvD1 can enhance the resolution of lung injury as a result of oxidative 
stress. Resolvin in the oxygen toxicity setting had not been studied previously. We exposed mice 
to a hyperoxic atmosphere (≥ 95%) for 48hrs. At this time point under hyperoxic conditions, 
mice develop a moderate form of lung injury that heals with little tissue scarring [13]. Following 
this exposure mice we left to resolve in normoxic conditions or given AT-RvD1 intravenously. 
While mice allowed to resolve from injury in a 24hr period showed moderate signs of injury 
resolution, mice given AT-RvD1 showed significant improvement from injury. Oxidative stress 
was reduced in this mice and respiratory biomechanics such as lung resistance was significantly 
improved. Hallmarks of ALI showed significant resolution in mice treated with AT-RvD1 as 
opposed to those mice left to recover in normoxic conditions without AT-RvD1 treatment. 
Tissue inflammation, alveolar permeability and edema, epithelial apoptosis, were all reduced in 
AT-RvD1 treated mice. Proinflammatory cytokine signaling was reduced in AT-RvD1 treated 
mice in comparison to vehicle controls. BAL fluid cytosmears show reduced leukocyte content 
and cell debris in AT-RvD1 treated mice in comparison to vehicle controls. Whether or not this 
is due to reduced adherence and uptake of leukocytes as shown in in vitro studies or it is a result 
of enhanced macrophage mediated neutrophil clearance needs to be investigated and represents a 
key future study. While resolvins demonstrate potential proresolution effects in HALI, these 
studies reveal an entirely new area of beneficial effects for resolvins. For the first time, these data 
demonstrate that AT-RvD1 enhances resolution of injury associated with oxygen toxicity. They 
also demonstrate that treatment with the pro-resolution agonist, AT-RvD1, both reverses 
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hyperoxia mediated proinflammatory and proapoptotic signaling and aids in the homestatic 
return to normal lung physiology (shown in figure 4.1). More importantly our results highlight an 
alteration in antioxidant production and transcription factor expression coupled with decrease 
oxidative stress. These results provide evidence for a novel role of AT-RvD1 in regulating 
hyperoxia-induced lung inflammation and acute injury. Thus far our studies as well as others 
have demonstrated a one hit system of acute injury, however patients also suffer from a myriad 
of complications that are both sterile and pathogen induced. It’s of interest to us to investigate 
the effects of AT-RvD1 in a two hit system that combined sepsis as well as sterile injury, such as 
hyperoxia and LPS.  It is also of interest to look at the mechanistic insights of resolvin mediated 
proresolution of injury. Formyl peptide receptor 2 (FPR2/ALX) is a well-documented high-
affinity receptor for both RvD1 and AT-RvD1. FPR2/ALX activation conveys significant anti-
inflammatory properties as reported previously [4,14-16]. Preliminary investigation of 
FPR2/ALXs role in the beneficial effects of AT-RvD1 were promising (Figure 4.3) A549 cells 
exposed to hyperoxia and IL-1β demonstrate enhanced surface expression of ALX/FPR2. Similar 
to recent reports where acid induced injury lead to an increase in ALX/FPR2 expression [5]. 
ALX/FPR2 expression may be expressed in response to inflammatory signals in an anticipatory 
fashion to serve as a homeostatic mechanisms when lipid mediators are produced. In A549 cells 
treated with IL-1β in the presence or absence of AT-RvD1, AT-RvD1 reduced IL-1β mediated 
NF-κB. This effect was significantly diminished when ALX/FPR2 inhibitor N-t-Boc-Phe-Leu-
Phe-Leu-Ph (BOC-2). These studies suggest that further investigation of role of ALX/FPR2 in 
AT-RvD1’s beneficial effects in an oxidant toxicity setting is warranted. 
From a clinical perspective, activating RvD1 producing pathways by a pharmacological 
approach may serve to disrupt the inflammatory cascade and ultimately may provide a novel 
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therapeutic strategy for the protection of lung tissue from cellular injury during acute or chronic 
illness associated with ALI syndromes. Further understanding of the mechanisms of AT-RvD1 
mediated HALI resolution may lead to the development of clinical interventions for the 
protection of patients requiring supplemental oxygen 
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Figures 
 
Figure 4.1: Aspirin triggered Resolvin D1 attenuates progressive HALI hallmarks that 
impede injury resolution. In a normal lung, hyperoxic exposure leads to macrophage secretion 
of IL-1b which triggers the epithelial cell response. Disruption of the epithelial barrier occurs 
and allows an influx a neutrophils along with increased macrophage activation and secretion of 
proinflammatory cytokines. Epithelial and inflammatory cells undergo apoptosis, leading to an 
overall accumulation of dead cell debris, ROS, cytotoxic enzymes, and a continuation of the 
inflammatory response. Treatment with AT-RvD1 results in decreased macrophage secretion of 
proinflammatory cytokines, such as IL-1b, and reduced activation of alveolar epithelial cells. 
Thus, lung permeability, neutrophil infiltration, macrophage activation and release of cytokines 
are significantly attenuated, enhancing injury resolution and clearance of leukocytes.  
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Figure 4.2: Future Directions. ALX/FPR2 is a well-documented receptor for both RvD1 and 
AT-RvD1 with higher binding affinity than formyl peptide substrate. Preliminary studies reveal 
an increase in alveolar epithelial surface expression of this receptor following 24hr hyperoxia 
exposure.  Blunting the receptor with chemical inhibitor boc-1 results in enhanced IL-1β 
mediated signaling of proinflammatory mediator NF-κB. 
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Figure 4.3: Clinical Significance. The development of pharmacological components that 
enhance the biosynthesis of resolvins could lead to a significant improvement in patient care and 
effectiveness of oxygen therapy due to decreased oxidant mediated injury. 
 
 
 
 
  
Clinical Significance 
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